
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">



<head id="Head1"><meta name="google-site-verification" content="_VGwTV0Z3wNC7pQw33rX86U_BGdiQMqGvEu9XPCrV54" />
                
    <!--MOBIFY - DO NOT ALTER - PASTE IMMEDIATELY AFTER OPENING HEAD TAG -->
    <style type="text/css">
        .bannerTopo {
            width: 100%;
            height: auto;
            float: left;

        }
        .colorbox_login {
        }
    </style>
    
    <script type="text/javascript">
        /*<![CDATA[*/
        (function (n, p) {
            function d(a) {
                if (a.mode) {
                    var b = c("mobify-mode");
                    b && a[b] || (b = a.mode(l.ua));
                    return a[b]
                }
                return a
            }

            function g() {
                function a(b) {
                    n.addEventListener(b, function () {
                        l[b] = +new Date
                    }, !1)
                }
                n.addEventListener && (a("DOMContentLoaded"), a("load"))
            }

            function h() {
                var a = new Date;
                a.setTime(a.getTime() + 300000);
                p.cookie = "mobify-path=; expires=" + a.toGMTString() + "; path=/";
                n.location.reload()
            }

            function k() {
                e({
                    src: "https://preview.mobify.com/v7/"
                })
            }

            function c(a) {
                if (a = p.cookie.match(RegExp("(^|; )" + a + "((=([^;]*))|(; |$))"))) {
                    return a[4] || ""
                }
            }

            function f(a) {
                p.write('<plaintext style="display:none">');
                setTimeout(function () {
                    m.capturing = !0;
                    a()
                }, 0)
            }

            function e(j, o) {
                var i = p.getElementsByTagName("script")[0],
                    a = p.createElement("script"),
                    b;
                for (b in j) {
                    a[b] = j[b]
                }
                o && a.setAttribute("class", o);
                i.parentNode.insertBefore(a, i)
            }
            var m = n.Mobify = {},
                l = m.Tag = {};
            m.points = [+new Date];
            m.tagVersion = [7, 0];
            l.ua = n.navigator.userAgent;
            l.getOptions = d;
            l.init = function (b) {
                l.options = b;
                if ("" !== c("mobify-path")) {
                    if (g(), b.skipPreview || "true" != c("mobify-path") && !/mobify-path=true/.test(n.location.hash)) {
                        var i = d(b);
                        if (i) {
                            var a = function () {
                                i.post && i.post()
                            };
                            b = function () {
                                i.pre && i.pre();
                                e({
                                    id: "mobify-js",
                                    src: i.url,
                                    onerror: h,
                                    onload: a
                                }, "mobify")
                            };
                            !1 === i.capture ? b() : f(b)
                        }
                    } else {
                        f(k)
                    }
                }
            }
        })(window, document);
        (function () {
            var b = "//cdn.mobify.com/sites/onofre-mobile/production/adaptive.min.js";
            Mobify.Tag.init({
                mode: function (a) {
                    return /^((?!windows\sphone).)*(ip(hone|od)|android.*(mobile)(?!.*firefox))/i.test(a) ? "enabled" : "desktop"
                },
                enabled: {
                    url: b
                },
                desktop: {
                    capture: !1,
                    url: "//a.mobify.com/onofre-mobile/a.js"
                }
            })
        })(); /*]]>*/
    </script>
    <!-- END MOBIFY -->
    <script language="javascript" type="text/javascript">window.chaordic_meta = { "page": { "name": "product", "timestamp": new Date(),"selected_specs": {"sales_channel": "24"},"categories": [{"name": "Medicamentos","id": "55"},{"name": "Antiarritmico","id": "27","parents": ["55"]}]},"product": {"id": "8052","name": "Cloridrato de Sotalol 160mg 30 Comprimidos - Merck - Genérico","url": "/cloridrato-de-sotalol-160mg-30-comprimidos-merck-generico/8052/05","description": "Cloridrato de Sotalol","images": {"300x300": "https://www.onofre.com.br/img/Busca/imagem_prescricao.jpg"},"categories": [{"name": "Medicamentos","id": "55"},{"name": "Antiarritmico","id": "27","parents": ["55"]}],"installment": {"count": 1,"price":35.80},"extra_info": {"otc": "no"},"details": {"rating": {"total": "0","value": "0",},"codigo_interno": "121398","registro_ms": "1008902810023","volume": "0","quantidade": "0","generico": "sim","consulta_genericos": "False","programa_beneficio": "False","marca": "Merck","urlMarca": "/busca/0/0/0/0/527/0/0/08"},"old_price": 67.55,"price": 35.80,"ean_code": "7891721023521","brand": "Merck","status": "available","skus": [{"sku": "121398","specs": {"sales_channel": "18"},"price": 35.80,"old_price": 74.29,"installment": {"count": 1,"price":35.80},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "20"},"price": 34.73,"old_price": 69.48,"installment": {"count": 1,"price":34.73},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "8"},"price": 37.51,"old_price": 61.76,"installment": {"count": 1,"price":37.51},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "27"},"price": 34.73,"old_price": 65.53,"installment": {"count": 1,"price":34.73},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "34"},"price": 34.73,"old_price": 65.53,"installment": {"count": 1,"price":34.73},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "38"},"price": 34.73,"old_price": 65.53,"installment": {"count": 1,"price":34.73},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "737"},"price": 34.73,"old_price": 65.53,"installment": {"count": 1,"price":34.73},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "750"},"price": 34.73,"old_price": 65.53,"installment": {"count": 1,"price":34.73},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "783"},"price": 34.73,"old_price": 69.48,"installment": {"count": 1,"price":34.73},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "144"},"price": 35.80,"old_price": 67.55,"installment": {"count": 1,"price":35.80},"status": "unavailable"},{"sku": "121398","specs": {"sales_channel": "24"},"price": 35.80,"old_price": 67.55,"installment": {"count": 1,"price":35.80},"status": "available"},{"sku": "121398","specs": {"sales_channel": "12"},"price": 35.80,"old_price": 67.55,"installment": {"count": 1,"price":35.80},"status": "available"}],"specs": {"sales_channel": ["18","20","8","27","34","38","737","750","783","144","24","12"]}}}</script>
    <!--Script Chaordic Loader-->
    <script async defer src="//static.chaordicsystems.com/static/loader.js" data-apikey="onofrefarma"></script>
    <!--<script type="text/javascript"> var headID = document.getElementsByTagName("head")[0]; var newScript = document.createElement('script'); newScript.type = 'text/javascript'; newScript.src = '//static.chaordicsystems.com/static/loader.js'; newScript.setAttribute('data-apikey', 'onofrefarma'); newScript.async = true; newScript.defer = true; headID.appendChild(newScript); </script> -->
    <!--Script Chaordic Loader - FIM -->
    <meta name="viewport" content="width=device-width, initial-scale=1.0" /><meta http-equiv="X-UA-Compatible" content="IE=8" /><title>
	Cloridrato de Sotalol 160mg 30 Comprimidos - Merck - Genérico | Onofre 
</title>

    <script src="Jss/gaEventos.js"></script>
    <link type="image/x-icon" href="https://www.onofre.com.br/favicon.ico" rel="icon" /><link type="image/x-icon" href="https://www.onofre.com.br/favicon.ico" rel="SHORTCUT ICON" />
        <!-- CSS -->
        <link href="/Jss/Colorbox/colorbox.css" rel="stylesheet"/>
<link href="/Jss/ToolTip/bubbletip/bubbletip.css" rel="stylesheet"/>
<link href="/Jss/ToolTip/bubbletip/bubbletip-IE.css" rel="stylesheet"/>
<link href="/Css/resetNovo.css" rel="stylesheet"/>
<link href="/Css/star_rating.css" rel="stylesheet"/>
<link href="/Css/EstiloMasterNovo.css" rel="stylesheet"/>
<link href="/Css/MasterNova.css" rel="stylesheet"/>
<link href="/shadowbox/shadowbox.css" rel="stylesheet"/>
<link href="/Css/rodape.css" rel="stylesheet"/>
<link href="/Css/EstiloExtraBucks.css" rel="stylesheet"/>
<link href="/assets/css/base.css" rel="stylesheet"/>
<link href="/assets/css/common.css" rel="stylesheet"/>

        <link href="/Css/AutenticacaoPBM.css" rel="stylesheet" />
        <!-- CSS -->
        <!-- JSS -->
        <script src="/Jss/jquery_onofre.js"></script>
<script src="/Jss/jquery.maskMoney.js"></script>
<script src="/shadowbox/shadowbox.js"></script>
<script src="/Jss/jquery.cookie.js"></script>
<script src="/Jss/Colorbox/jquery.colorbox-min.js"></script>
<script src="/Jss/Dialog/jquery-ui-1.10.1.custom.min.js"></script>
<script src="/Jss/generic.js"></script>
<script src="/Jss/jqzoom.pack.1.0.1.js"></script>
<script src="/Jss/jquery.hoverIntent.minified.js"></script>
<script src="/Jss/ToolTip/jQuery.bubbletip-1.0.6.js"></script>
<script src="/Jss/ToolTip/ToolTip.js"></script>
<script src="/assets/js/lib/owl.carousel.min.js"></script>
<script src="/assets/js/main.js"></script>
<script src="/Jss/Utils/MasterPage.js"></script>

        <script src="/Jss/AutenticaFloatBar.js"></script>
        <link href="/Css/select2.min.css" rel="stylesheet" />
        <script src="/Jss/Utils/select2.min.js"></script>
        <link href="/Css/MasterResponsivo.css" rel="stylesheet" />
        <script src="/Jss/Utils/Home.js"></script>
        <script type="text/javascript" src='https://www.google.com/recaptcha/api.js'></script>
        <!-- JSS -->
    
    <!--[if lt IE 9]> <script src="https://html5shim.googlecode.com/svn/trunk/html5.js"></script> <![endif]-->
    <!-- JSS -->
    
    
    
    <script type='text/javascript' src='https://v2.afilio.com.br/mastertag.php?progid=1719&type=product&id_partner=drogariaonofre&product_id1=8052&id_category=0&stock=0&product_sku=&product_name=CLOR SOTALOL 160MG 30S MCK GE&product_desc=Cloridrato de Sotalol 160mg 30 Comprimidos - Merck - Genérico&product_photo=https://www.onofre.com.br/estatico/Produto/Normal/&price1=35,80&price2=67,55&product_currency=BRL&url_product=http://www.onofre.com.br/DetalheProduto/Default.aspx?ProductName=cloridrato-de-sotalol-160mg-30-comprimidos-merck-generico&ProductId=8052'></script>
    <link href="/Css/EstiloDetalheProduto.css" rel="stylesheet"/>
<link href="/Css/jqzoom.css" rel="stylesheet"/>
<link href="/Jss/Colorbox/colorbox.css" rel="stylesheet"/>
<link href="/assets/css/prateleira.css" rel="stylesheet"/>
<link href="/assets/css/produto.css" rel="stylesheet"/>
<script type="text/javascript" src="/Jss/DetalheProduto.js" defer></script>
<script type="text/javascript" src="/Jss/jqzoom.pack.1.0.1.js" defer></script>
<script type="text/javascript" src="/Jss/zoom/jquery.jqzoom-core.js" defer></script>
<script type="text/javascript" src="/jss/zoom/zoom.js" defer></script>
<script type="text/javascript" src="/Jss/Colorbox/jquery.colorbox-min.js" defer></script>
<script type="text/javascript" src="/Jss/Utils/DetalheProduto.js" defer></script>
<script type="text/javascript" src="/assets/js/produto.js" defer></script>

    <script type="text/javascript">        /*<![CDATA[*/ var dataLayer = [{
                               'site' : { 'domain' : document.location.host },
                               'page' : { 
                                            'name' : document.title,
                                            'pageType' : 'product'
                                        },
                                               'product' : {
                                               'productName' : 'CLOR SOTALOL 160MG 30 S MCK GE',
                                               'productId' : '8052',
                                               'productCategory' : '',
                                               'productSubCategory' : '',
                                               'productPrice' : '35.80',
                                               'productBrand' : 'Merck'
                                           },
                               'session' : {
                                                'isLogged': false,
                                                'user' : { 'id' : 'VISIT-1616646000' }
                                           }
                                }];; /*]]>*/ </script>
<link rel="stylesheet" type="text/css" href="//onofre.resultspage.com/autocomplete/sli-rac.css" /><meta name="description" content="Cloridrato de Sotalol 160mg 30 Comprimidos - Merck - Genérico da Merck com o menor preço é na Onofre. Receba seu pedido em casa pagando em até 3x. Compre agora!" /></head>
            

<body id="body" class="produto">

    <!-- BANNER TOPO -->
    
    <div class="bannerTopo" style="max-height: 100px">
        
    </div>
    <!-- FIM - BANNER TOPO -->
    <script type="text/javascript" src="//onofre.resultspage.com/autocomplete/sli-rac.config.js"></script>
    
    <!-- Start Alexa Certify Javascript -->
    <script type="text/javascript" src="https://d31qbv1cthcecs.cloudfront.net/atrk.js"></script>
    <script type="text/javascript">
        _atrk_opts = {
            atrk_acct: "xfCse1aALO00g7",
            domain: "onofre.com.br"
        };
        atrk();
    </script>
    <noscript>
        <img src="https://d5nxst8fruw4z.cloudfront.net/atrk.gif?account=xfCse1aALO00g7" style="display: none" height="1" width="1" alt="" />
    </noscript>
    <script type="text/javascript">
        /* Set the width of the side navigation to 250px */
        function openNavMobile() {
            document.getElementById("mySidenav").style.width = "255px";
        } /* Set the width of the side navigation to 0 */
        function closeNavMobile() {
            document.getElementById("mySidenav").style.width = "0";
        }
    </script>
    <!-- End Alexa Certify Javascript -->
    <form method="post" action="/cloridrato-de-sotalol-160mg-30-comprimidos-merck-generico/8052/05" id="form1">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" />

<script> ECO_Step='Product';</script><script> ECO_DepName='';</script><script> ECO_DepId='';</script><script> ECO_CatName='';</script><script> ECO_CatId='';</script><script> ECO_ProdName='cloridrato-de-sotalol-160mg-30-comprimidos-merck-generico';</script><script> ECO_ProdId='8052';</script><script> ECO_ProdValue='35.80';</script><script> ECO_ProdSumValue='35.80';</script><script> ECO_ProdQty='1';</script><script> ECO_ProdAvgValue='35,80';</script>
<script type="text/javascript">
//<![CDATA[
products = []; products.push( {'id':121398,'name':'Cloridrato de Sotalol 160mg 30 Comprimidos - Merck - Genérico','category':'Antiarritmico','price':35.80,'quantity':0,'brandId':527});var productData ={   'transaction': {'id':0,     'products': products}};//]]>
</script>

<script src="/ScriptResource.axd?d=BnWrJ6-gLV3GlI8g28LCzYXkfKJLttyoigz0AJpfnvO4NN21YTBbDD9JctBIuGGW8YufhqFw-AnVHbmyWvfFb_B2w9DMLRk3OO9iqYmkxfGcvnVf4ImxaGFLKlWYiwlxPddzmc-9JHkJ8clChxff5mADpJw1&amp;t=42a7acab" type="text/javascript"></script>
<input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="53BE6E71" />
<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAu0IXsfd4ffYP5iQIpV7XsFvGJREAXUqdHbn/uqryQegasCjseFQU1IG6a1QV/1IsPDvqD576IjU8b+VycT56M9ED22EwkGKj1YkpT+X+kXiM56f9BvruTcOsm75dsnP4j+rR3kChNt2jv+P1A6lf1Kfh0m/YFL+gqaOapTOLGCT3uEmapvkS7PnXX2p48aV5JXiYT1tmrUuDA14lwoxMmxwwFaVvdlxqKyIPzmKQOht82vdUs3eu9rYfwgNNjSL88h17cc" />
        
        <!-- Master -->
        
        <!-- Header -->
        <div id="mySidenav" class="sidenav">
            
            <a href="javascript:void(0)" id="divMobileLogin"><span style="float: left; font-size: 18px; text-decoration: underline" onclick="window.location.href='https://www.onofre.com.br/acesso/'">Faça o login ou cadastre-se</span>
                <br />
                <span class="closebtn" onclick="closeNavMobile()">&times;</span></a>
            <!--<a href="#">About</a> <a href="#">Services</a> <a href="#">Clients</a> <a href="#">Contact</a>-->
            <hr />
            <nav id="mobile-nav" class="page-nav">
                                    <div class="wrapper full">
                                        <ul class="nav-list">
                                            <li class="medicamentos-e-saude"><a onclick="$('.medicamentos-e-saude .sub-nav').toggle();" title="Medicamentos" class="nav-link">Medicamentos</a>
                                                <div class="sub-nav">
                                                    <ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Intestino e Digestão</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/saude-digestiva/44/03' class='medi-sub-nav-link' >Saúde Digestiva</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiflatulento/54/03' class='medi-sub-nav-link' >Antiflatulento</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiacido/95/03' class='medi-sub-nav-link' >Antiácido</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/laxante/248/03' class='medi-sub-nav-link' >Laxante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Diabetes</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipoglicemiante/234/03' class='medi-sub-nav-link' >Hipoglicemiante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Hormônios</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antigotoso/57/03' class='medi-sub-nav-link' >Antigotoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/tireoidiano/342/03' class='medi-sub-nav-link' >Tireoidiano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Infecções</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antibiotico/32/03' class='medi-sub-nav-link' >Antibiótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-infeccioso/67/03' class='medi-sub-nav-link' >Anti-infeccioso</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Aparelho Urinário</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidiuretico/46/03' class='medi-sub-nav-link' >Antidiurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antilitiasico/80/03' class='medi-sub-nav-link' >Antilitiásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/diuretico/190/03' class='medi-sub-nav-link' >Diurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/incontinencia-urinaria/242/03' class='medi-sub-nav-link' >Incontinência Urinária</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Nervoso</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivertiginoso/112/03' class='medi-sub-nav-link' >Antivertiginoso</a></li><li class='medi-sub-nav-item'><a href='/homeopaticos/calmante/147/03' class='medi-sub-nav-link' >Calmante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-tubo-neural/188/03' class='medi-sub-nav-link' >Distúrbio do Tubo Neural</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/neuropsicoestimulante/278/03' class='medi-sub-nav-link' >Neuropsicoestimulante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Gripe e Resfriado</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitussigenos/109/03' class='medi-sub-nav-link' >Antitussígenos</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante/179/03' class='medi-sub-nav-link' >Descongestionante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/irritacoes-da-garganta/246/03' class='medi-sub-nav-link' >Irritações da Garganta</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/expectorante-e-mucolitico/274/03' class='medi-sub-nav-link' >Expectorante e Mucolítico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Anti-Hipertensivo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiarritmico/27/03' class='medi-sub-nav-link' >Antiarritmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hipertensivo/62/03' class='medi-sub-nav-link' >Anti-hipertensivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/cardiotonico/149/03' class='medi-sub-nav-link' >Cardiotônico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipertensor/231/03' class='medi-sub-nav-link' >Hipertensor</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Cuidado com os Olhos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/orgaos-sensoriais/56/03' class='medi-sub-nav-link' >Órgãos Sensoriais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante-ocular/180/03' class='medi-sub-nav-link' >Descongestionante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/distrofia-do-globo-ocular/189/03' class='medi-sub-nav-link' >Distrofia do Globo Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/lubrificante-ocular/260/03' class='medi-sub-nav-link' >Lubrificante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Circulatório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antianemico/26/03' class='medi-sub-nav-link' >Antianêmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hemorragico/61/03' class='medi-sub-nav-link' >Anti-hemorrágico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivaricoso/111/03' class='medi-sub-nav-link' >Antivaricoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hemostatico/221/03' class='medi-sub-nav-link' >Hemostático</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vermes e Parasitas</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifungico/52/03' class='medi-sub-nav-link' >Antifúngico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antimalarico/81/03' class='medi-sub-nav-link' >Antimalárico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparasitario/90/03' class='medi-sub-nav-link' >Antiparasitário</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Dor e Febre</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/analgesico/8/03' class='medi-sub-nav-link' >Analgésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anestesico/13/03' class='medi-sub-nav-link' >Anestésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antienxaquecoso/48/03' class='medi-sub-nav-link' >Antienxaquecoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-inflamatorio/69/03' class='medi-sub-nav-link' >Anti-inflamatório</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Alergias</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialergico/21/03' class='medi-sub-nav-link' >Antialérgico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Respiratório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiasmatico/29/03' class='medi-sub-nav-link' >Antiasmático</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/broncodilatador/142/03' class='medi-sub-nav-link' >Broncodilatador</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Pele e Mucosa</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/cicatrizante/155/03' class='medi-sub-nav-link' >Cicatrizante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/despigmentante/182/03' class='medi-sub-nav-link' >Despigmentante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/aftas/215/03' class='medi-sub-nav-link' >Aftas</a></li><li class='medi-sub-nav-item'><a href='/tratamento-rosto/antiacne/399/03' class='medi-sub-nav-link' >Antiacne</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vitaminas e Suplementos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifadiga/53/03' class='medi-sub-nav-link' >Antifadiga</a></li><li class='medi-sub-nav-item'><a href='/nutricosmeticos/antioxidante/88/03' class='medi-sub-nav-link' >Antioxidante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/orexigeno/281/03' class='medi-sub-nav-link' >Orexígeno</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/vitaminico/367/03' class='medi-sub-nav-link' >Vitamínico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Masculina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialopecia/20/03' class='medi-sub-nav-link' >Antialopécia</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiandrogenico/24/03' class='medi-sub-nav-link' >Antiandrogénico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disfuncao-eretil/185/03' class='medi-sub-nav-link' >Disfunção Erétil</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hiperplasia-prostatica-benigna/230/03' class='medi-sub-nav-link' >Hiperplasia Prostática Benigna</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Feminina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/anticoncepcionais/39/03' class='medi-sub-nav-link' >Anticoncepcionais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-ciclo-menstrual/187/03' class='medi-sub-nav-link' >Distúrbio do Ciclo Menstrual</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/indutor-da-ovulacao/243/03' class='medi-sub-nav-link' >Indutor da Ovulação</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/terapeutica-da-menopausa/337/03' class='medi-sub-nav-link' >Terapêutica da Menopausa</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Ósseo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiartrosico/28/03' class='medi-sub-nav-link' >Antiartrósico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiosteoporotico/87/03' class='medi-sub-nav-link' >Antiosteoporótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/osteoporose/94/03' class='medi-sub-nav-link' >Osteoporose</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/repositor-de-potassio/315/03' class='medi-sub-nav-link' >Repositor de Potássio</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Controle Especial</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidepressivo/42/03' class='medi-sub-nav-link' >Antidepressivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparkinsoniano/91/03' class='medi-sub-nav-link' >Antiparkinsoniano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Outros</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antineoplasico/84/03' class='medi-sub-nav-link' >Antineoplásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitabagismo/103/03' class='medi-sub-nav-link' >Antitabagismo</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul>
                                                         </div>
                                            </li>
                                            <li class="medicamentos-e-saude_new"><a onclick="$('.medicamentos-e-saude_new .sub-nav').toggle();" title="Saúde" class="nav-link">Saúde</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class='sub-nav-item'><a href='/geriatria/46/01' class='sub-nav-link' title='Geriatria'>Geriatria</a></li><li class='sub-nav-item'><a href='/higiene-e-limpeza/48/01' class='sub-nav-link' title='Higiene e Limpeza'>Higiene e Limpeza</a></li><li class='sub-nav-item'><a href='/homeopaticos/50/01' class='sub-nav-link' title='Homeopáticos'>Homeopáticos</a></li><li class='sub-nav-item'><a href='/alimentos-e-bebidas/52/01' class='sub-nav-link' title='Alimentos e Bebidas'>Alimentos e Bebidas</a></li><li class='sub-nav-item'><a href='/medicamentos/55/01' class='sub-nav-link' title='Medicamentos'>Medicamentos</a></li><li class='sub-nav-item'><a href='/cuidado-com-os-olhos/57/01' class='sub-nav-link' title='Cuidado com os Olhos'>Cuidado com os Olhos</a></li><li class='sub-nav-item'><a href='/ortopedia-e-acessorios/58/01' class='sub-nav-link' title='Ortopedia e Acessórios'>Ortopedia e Acessórios</a></li><li class='sub-nav-item'><a href='/primeiros-socorros/60/01' class='sub-nav-link' title='Primeiros Socorros'>Primeiros Socorros</a></li><li class='sub-nav-item'><a href='/sexo-seguro/61/01' class='sub-nav-link' title='Sexo Seguro'>Sexo Seguro</a></li><li class='sub-nav-item'><a href='/fitness-e-dietas/62/01' class='sub-nav-link' title='Fitness e Dietas'>Fitness e Dietas</a></li><li class='sub-nav-item'><a href='/testes-e-aparelhos/63/01' class='sub-nav-link' title='Testes e Aparelhos'>Testes e Aparelhos</a></li><li class='sub-nav-item'><a href='/vitaminas-e-naturais/65/01' class='sub-nav-link' title='Vitaminas e Naturais'>Vitaminas e Naturais</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A2"> <img id="Img2" /></a>
                                                        > </div>
                                                </div>
                                            </li>
                                            <li class="beleza-e-bem-estar"><a onclick="$('.beleza-e-bem-estar .sub-nav').toggle();" title="Beleza e Bem Estar" class="nav-link">Beleza e Bem Estar</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class='sub-nav-item'><a href='/tratamento-rosto/39/01' class='sub-nav-link' title='Tratamento Rosto'>Tratamento Rosto</a></li><li class='sub-nav-item'><a href='/cabelos/40/01' class='sub-nav-link' title='Cabelos'>Cabelos</a></li><li class='sub-nav-item'><a href='/corpo-e-banho/42/01' class='sub-nav-link' title='Corpo e Banho'>Corpo e Banho</a></li><li class='sub-nav-item'><a href='/cuidados-femininos/44/01' class='sub-nav-link' title='Cuidados Femininos'>Cuidados Femininos</a></li><li class='sub-nav-item'><a href='/cuidados-masculinos/49/01' class='sub-nav-link' title='Cuidados Masculinos'>Cuidados Masculinos</a></li><li class='sub-nav-item'><a href='/maos-e-pes/53/01' class='sub-nav-link' title='Mãos e Pés'>Mãos e Pés</a></li><li class='sub-nav-item'><a href='/maquiagem/54/01' class='sub-nav-link' title='Maquiagem'>Maquiagem</a></li><li class='sub-nav-item'><a href='/nutricosmeticos/56/01' class='sub-nav-link' title='Nutricosméticos'>Nutricosméticos</a></li><li class='sub-nav-item'><a href='/colonias/59/01' class='sub-nav-link' title='Colônias'>Colônias</a></li><li class='sub-nav-item'><a href='/tratamento-do-corpo/64/01' class='sub-nav-link' title='Tratamento do Corpo'>Tratamento do Corpo</a></li><li class='sub-nav-item'><a href='/higiene-bucal/68/01' class='sub-nav-link' title='Higiene Bucal'>Higiene Bucal</a></li><li class='sub-nav-item'><a href='/protecao-solar/69/01' class='sub-nav-link' title='Proteção Solar'>Proteção Solar</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A3"> <img id="Img3" /></a>
                                                         </div>
                                                </div>
                                            </li>
                                            <li class="mamae-e-bebe"><a onclick="$('.mamae-e-bebe .sub-nav').toggle();" title="Mamãe e Bebê" class="nav-link">Mamãe e Bebê</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class='sub-nav-item'><a href='/acessorios-infantis/37/01' class='sub-nav-link' title='Acessórios Infantis'>Acessórios Infantis</a></li><li class='sub-nav-item'><a href='/alimentos-infantis/38/01' class='sub-nav-link' title='Alimentos Infantis'>Alimentos Infantis</a></li><li class='sub-nav-item'><a href='/corpo-e-banho-infantil/41/01' class='sub-nav-link' title='Corpo e Banho Infantil'>Corpo e Banho Infantil</a></li><li class='sub-nav-item'><a href='/cuidados-com-a-mamae/43/01' class='sub-nav-link' title='Cuidados com a Mamãe'>Cuidados com a Mamãe</a></li><li class='sub-nav-item'><a href='/troca-de-fraldas/45/01' class='sub-nav-link' title='Troca de Fraldas'>Troca de Fraldas</a></li><li class='sub-nav-item'><a href='/cuidado-bucal-infantil/47/01' class='sub-nav-link' title='Cuidado Bucal Infantil'>Cuidado Bucal Infantil</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A4"> <img id="Img4" /></a>
                                                         </div>
                                                </div>
                                            </li>
                                            <li class="ofertas-e-lancamentos"><a onclick="$('.ofertas-e-lancamentos .sub-nav').toggle();" title="Ofertas e Lançamentos" class="nav-link"> Ofertas e Lançamentos</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/oferta/66" class="sub-nav-link" title="Ofertas">Ofertas</a></li>
                                                    </ul>
                                                    <ul class="sub-nav-col">
                                                        <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/lancamento/66" class="sub-nav-link" title="Lançamentos">Lançamentos</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A5"> <img id="Img5" /></a>
                                                         </div>
                                                </div>
                                            </li>
                                            <li class="como-comprar"><a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=251" title="Como Comprar" class="nav-link">Como Comprar</a> </li>
                                        </ul>
                                    </div>
                                </nav>
        </div>
        <header id="main-header" class="page-header">
                                <!--<div class="topbar-responsive"> <div class="wrapper-responsive full"> <div class="televendas col"> <p><span>Televendas:</span> <strong>4007-2526</strong></p> </div> <div class="social-responsive"> <ul class="social-list"> <li class="social-item"><a href="https://www.facebook.com/DrogariaOnofreOficial" class="social-link facebook" target="_blank" title="Facebook">Facebook</a></li> <li class="social-item"><a href="https://blogonofre.wordpress.com/" class="social-link beonofre" target="_blank" title="BeOnofre">BeOnofre</a></li>  </ul> </div> </div> </div>-->
                                <div class="topbar">
                                    <div class="wrapper full">
                                        <div class="welcome col" style="width: 570px; margin-top: 20px;">
                                            <!-- usuario logado-->
                                            
                                            <!-- fim usuario logado-->

                                            <!-- usuario não logado-->
                                            <div id="divTopoLogin" class="login col">
                                                <div id="Panel2" class="login-form">
	
                                                    <div style="display: none">
                                                        <label for="identificacao">Faça seu login:</label>
                                                        <input name="ctl00$TxtUsuario" type="text" id="TxtUsuario" class="campo_texto" autocomplete="off" placeholder="Digite seu email ou cpf" />
                                                    </div>
                                                    <div id="divPasswordDoLogin" style="display: none">
                                                        <label for="senha">Senha</label>
                                                        <input name="ctl00$TxtSenha" type="password" id="TxtSenha" class="campo_texto" />
                                                    </div>
                                                    
                                                    <a class="welcome-msg" style="font-size: 12px; vertical-align: middle; font-family: Tahoma"> OLÁ VISITANTE, </a> 
                                                    <a class="action-link criar-conta" style="font-size: 12px; font-family: Tahoma" id="btnBoxLogin" onclick="ExibirPopupLogin('../../../../../../../../Login/LoginBox.aspx',680,460)">FAÇA LOGIN</a> <a>|</a>
                                                    <a href="/cadastro/" class="action-link criar-conta" style="font-size: 12px; font-family: Tahoma">CRIAR CONTA</a> <a>|</a>
                                                    <div><a class="forgot-password action-link" href="#" style="font-size: 12px; font-family: Tahoma;vertical-align: middle;display: inline-block" onclick="ExibirPopup('../../../../../../../../login/ForgotPassWord.aspx',450,290)">ESQUECI MINHA SENHA</a> </div>
                                                      
</div>
                                            </div>

                                            

                               
                                           
                                        </div>
                                             <!-- fim usuario não logado -->
                                        <div class="televendas col" style="margin-top: 20px;">
                                            <p><span>Televendas:</span> <strong>4007-2526</strong></p>
                                        </div>
                                        
                                            <div class="social col" style="margin-top: 15px;">

                                                <ul class="social-list">
                                                    <li class="social-item"><a href="https://www.facebook.com/DrogariaOnofreOficial" class="social-link facebook" target="_blank" title="Facebook">Facebook</a></li>
                                                    <li class="social-item"><a href="https://www.instagram.com/drogariaonofre/" class="social-link instagram" target="_blank" title="Instagram">Instagram</a></li>
                                                    <li class="social-item"><a href="https://blogonofre.wordpress.com/" class="social-link beonofre" target="_blank" title="BlogOnofre">BeOnofre</a></li>
                                                    
                                                </ul>
                                            </div>
                                    </div>
                                </div>
                                <!-- /topbar -->
                                <div class="wrapper full">
                                    <div class="menu-responsive col" onclick="openNavMobile()"> </div>
                                    <div class="logo col">
                                        <h1>  <a href="https://www.onofre.com.br/" class="logo-img">Onofre</a>  </h1> </div>
                                    <div class="cart-responsive">
                                        <div class="cart col"> <a href="/carrinho" class="go-to-cart"><span class="total-value"> <span id="lblCartTotalResponsive">R$ 0,00</span> </span></a> </div>
                                    </div>
                                    <div class="search col">
                                        <div class="msg-cvs">
                                            <p> <img src="https://www.onofre.com.br/assets/img/cvs-health-logo.jpg" alt="CVS Health" width="105" height="21" /> A drogaria onofre agora faz parte da rede de farmácias CVS Health. <a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=230" class="action-link">Clique aqui e saiba mais.</a> </p>
                                        </div>
                                        <!-- /search -->
                                        <div class="search-box">
                                            <!-- search box starts here -->
                                            
                                         
                                             <div id="pnBuscaSli">
	
                                                <input type="hidden" name="asug"  />
                                                <input name="ctl00$sli_search_1" type="text" id="sli_search_1" data-provide="rac" value="Digite o nome do produto, marca ou princípio ativo..." class="search-field search-input" data-sli-test="searchbox" onblur="if(value==&#39;&#39;)value=&#39;Digite o nome do produto, marca ou princípio ativo...&#39;" onfocus="if(value==&#39;Digite o nome do produto, marca ou princípio ativo...&#39;)value=&#39;&#39;" onkeydown="javascript:return fnTrapKD(event,this)" autocomplete="off" /> <a id="btnOkSli" class="search-icon" href="javascript:SliSearchById('sli_search_1')" data-sli-test="searchbutton">Ok</a> 
</div>
                                          <!-- search box ends here -->
                                        </div>
                                    </div>
                                    <!-- /search -->
                                    <!-- carrinho -->
                                    <div class="cart col cart-normal"> <a href="/carrinho" class="go-to-cart"><span class="total-value"> <span id="lblShoppingCartTotal">R$ 0,00</span> </span></a>
                                        <div class="cart-hover">
                                            <div id="CartPopUp" class="cart-list">
                                                 </div>
                                            <div class="cart-bottom">
                                                <div class="line" style="display:none">
                                                     <span class="total">Total: <strong class="total-value"> <span id="lblCartTotal">R$ 0,00</span></strong></span>
                                                </div>
                                                <div class="line">
                                                    <!--<div class="one-click"><a href="" class="btn btn-gray buy-one-click">Comprar com 1 clique</a></div>-->
                                                    <div class="buy-cart"><a href="/carrinho" class="btn btn-green">Finalizar compra</a> </div>
                                                </div>
                                            </div> <span id="lblProdAdicionado" class="prod-added">Produto adicionado ao carrinho</span> </div>
                                    </div>
                                </div>
                                
                            </header>
        <nav id="main-nav" class="page-nav">
                                <div class="wrapper full">
                                    <ul class="nav-list">
                                        
                                        <li class="nav-item medicamentos-e-saude"><a href='https://www.onofre.com.br' title='Medicamentos e Saúde' class='nav-link'>Medicamentos</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Intestino e Digestão</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/saude-digestiva/44/03' class='medi-sub-nav-link' >Saúde Digestiva</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiflatulento/54/03' class='medi-sub-nav-link' >Antiflatulento</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiacido/95/03' class='medi-sub-nav-link' >Antiácido</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/laxante/248/03' class='medi-sub-nav-link' >Laxante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Diabetes</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipoglicemiante/234/03' class='medi-sub-nav-link' >Hipoglicemiante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Hormônios</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antigotoso/57/03' class='medi-sub-nav-link' >Antigotoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/tireoidiano/342/03' class='medi-sub-nav-link' >Tireoidiano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Infecções</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antibiotico/32/03' class='medi-sub-nav-link' >Antibiótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-infeccioso/67/03' class='medi-sub-nav-link' >Anti-infeccioso</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Aparelho Urinário</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidiuretico/46/03' class='medi-sub-nav-link' >Antidiurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antilitiasico/80/03' class='medi-sub-nav-link' >Antilitiásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/diuretico/190/03' class='medi-sub-nav-link' >Diurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/incontinencia-urinaria/242/03' class='medi-sub-nav-link' >Incontinência Urinária</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Nervoso</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivertiginoso/112/03' class='medi-sub-nav-link' >Antivertiginoso</a></li><li class='medi-sub-nav-item'><a href='/homeopaticos/calmante/147/03' class='medi-sub-nav-link' >Calmante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-tubo-neural/188/03' class='medi-sub-nav-link' >Distúrbio do Tubo Neural</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/neuropsicoestimulante/278/03' class='medi-sub-nav-link' >Neuropsicoestimulante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Gripe e Resfriado</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitussigenos/109/03' class='medi-sub-nav-link' >Antitussígenos</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante/179/03' class='medi-sub-nav-link' >Descongestionante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/irritacoes-da-garganta/246/03' class='medi-sub-nav-link' >Irritações da Garganta</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/expectorante-e-mucolitico/274/03' class='medi-sub-nav-link' >Expectorante e Mucolítico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Anti-Hipertensivo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiarritmico/27/03' class='medi-sub-nav-link' >Antiarritmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hipertensivo/62/03' class='medi-sub-nav-link' >Anti-hipertensivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/cardiotonico/149/03' class='medi-sub-nav-link' >Cardiotônico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipertensor/231/03' class='medi-sub-nav-link' >Hipertensor</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Cuidado com os Olhos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/orgaos-sensoriais/56/03' class='medi-sub-nav-link' >Órgãos Sensoriais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante-ocular/180/03' class='medi-sub-nav-link' >Descongestionante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/distrofia-do-globo-ocular/189/03' class='medi-sub-nav-link' >Distrofia do Globo Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/lubrificante-ocular/260/03' class='medi-sub-nav-link' >Lubrificante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Circulatório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antianemico/26/03' class='medi-sub-nav-link' >Antianêmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hemorragico/61/03' class='medi-sub-nav-link' >Anti-hemorrágico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivaricoso/111/03' class='medi-sub-nav-link' >Antivaricoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hemostatico/221/03' class='medi-sub-nav-link' >Hemostático</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vermes e Parasitas</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifungico/52/03' class='medi-sub-nav-link' >Antifúngico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antimalarico/81/03' class='medi-sub-nav-link' >Antimalárico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparasitario/90/03' class='medi-sub-nav-link' >Antiparasitário</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Dor e Febre</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/analgesico/8/03' class='medi-sub-nav-link' >Analgésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anestesico/13/03' class='medi-sub-nav-link' >Anestésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antienxaquecoso/48/03' class='medi-sub-nav-link' >Antienxaquecoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-inflamatorio/69/03' class='medi-sub-nav-link' >Anti-inflamatório</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Alergias</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialergico/21/03' class='medi-sub-nav-link' >Antialérgico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Respiratório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiasmatico/29/03' class='medi-sub-nav-link' >Antiasmático</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/broncodilatador/142/03' class='medi-sub-nav-link' >Broncodilatador</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Pele e Mucosa</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/cicatrizante/155/03' class='medi-sub-nav-link' >Cicatrizante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/despigmentante/182/03' class='medi-sub-nav-link' >Despigmentante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/aftas/215/03' class='medi-sub-nav-link' >Aftas</a></li><li class='medi-sub-nav-item'><a href='/tratamento-rosto/antiacne/399/03' class='medi-sub-nav-link' >Antiacne</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vitaminas e Suplementos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifadiga/53/03' class='medi-sub-nav-link' >Antifadiga</a></li><li class='medi-sub-nav-item'><a href='/nutricosmeticos/antioxidante/88/03' class='medi-sub-nav-link' >Antioxidante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/orexigeno/281/03' class='medi-sub-nav-link' >Orexígeno</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/vitaminico/367/03' class='medi-sub-nav-link' >Vitamínico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Masculina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialopecia/20/03' class='medi-sub-nav-link' >Antialopécia</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiandrogenico/24/03' class='medi-sub-nav-link' >Antiandrogénico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disfuncao-eretil/185/03' class='medi-sub-nav-link' >Disfunção Erétil</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hiperplasia-prostatica-benigna/230/03' class='medi-sub-nav-link' >Hiperplasia Prostática Benigna</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Feminina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/anticoncepcionais/39/03' class='medi-sub-nav-link' >Anticoncepcionais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-ciclo-menstrual/187/03' class='medi-sub-nav-link' >Distúrbio do Ciclo Menstrual</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/indutor-da-ovulacao/243/03' class='medi-sub-nav-link' >Indutor da Ovulação</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/terapeutica-da-menopausa/337/03' class='medi-sub-nav-link' >Terapêutica da Menopausa</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Ósseo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiartrosico/28/03' class='medi-sub-nav-link' >Antiartrósico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiosteoporotico/87/03' class='medi-sub-nav-link' >Antiosteoporótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/osteoporose/94/03' class='medi-sub-nav-link' >Osteoporose</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/repositor-de-potassio/315/03' class='medi-sub-nav-link' >Repositor de Potássio</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Controle Especial</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidepressivo/42/03' class='medi-sub-nav-link' >Antidepressivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparkinsoniano/91/03' class='medi-sub-nav-link' >Antiparkinsoniano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Outros</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antineoplasico/84/03' class='medi-sub-nav-link' >Antineoplásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitabagismo/103/03' class='medi-sub-nav-link' >Antitabagismo</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul>
                                                     </div>
                                        </li>
                                        <li class="nav-item medicamentos-e-saude_new"><a href='https://www.onofre.com.br' title='Medicamentos e Saúde' class='nav-link'>Saúde</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class='sub-nav-item'><a href='/geriatria/46/01' class='sub-nav-link' title='Geriatria'>Geriatria</a></li><li class='sub-nav-item'><a href='/higiene-e-limpeza/48/01' class='sub-nav-link' title='Higiene e Limpeza'>Higiene e Limpeza</a></li><li class='sub-nav-item'><a href='/homeopaticos/50/01' class='sub-nav-link' title='Homeopáticos'>Homeopáticos</a></li><li class='sub-nav-item'><a href='/alimentos-e-bebidas/52/01' class='sub-nav-link' title='Alimentos e Bebidas'>Alimentos e Bebidas</a></li><li class='sub-nav-item'><a href='/medicamentos/55/01' class='sub-nav-link' title='Medicamentos'>Medicamentos</a></li><li class='sub-nav-item'><a href='/cuidado-com-os-olhos/57/01' class='sub-nav-link' title='Cuidado com os Olhos'>Cuidado com os Olhos</a></li><li class='sub-nav-item'><a href='/ortopedia-e-acessorios/58/01' class='sub-nav-link' title='Ortopedia e Acessórios'>Ortopedia e Acessórios</a></li><li class='sub-nav-item'><a href='/primeiros-socorros/60/01' class='sub-nav-link' title='Primeiros Socorros'>Primeiros Socorros</a></li><li class='sub-nav-item'><a href='/sexo-seguro/61/01' class='sub-nav-link' title='Sexo Seguro'>Sexo Seguro</a></li><li class='sub-nav-item'><a href='/fitness-e-dietas/62/01' class='sub-nav-link' title='Fitness e Dietas'>Fitness e Dietas</a></li><li class='sub-nav-item'><a href='/testes-e-aparelhos/63/01' class='sub-nav-link' title='Testes e Aparelhos'>Testes e Aparelhos</a></li><li class='sub-nav-item'><a href='/vitaminas-e-naturais/65/01' class='sub-nav-link' title='Vitaminas e Naturais'>Vitaminas e Naturais</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="A1"> <img id="Img1" /></a>
                                                    > </div>
                                            </div>
                                        </li>
                                        <li class="nav-item beleza-e-bem-estar"><a href='https://www.onofre.com.br' title='Beleza e Bem Estar' class='nav-link'>Beleza e Bem estar</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class='sub-nav-item'><a href='/tratamento-rosto/39/01' class='sub-nav-link' title='Tratamento Rosto'>Tratamento Rosto</a></li><li class='sub-nav-item'><a href='/cabelos/40/01' class='sub-nav-link' title='Cabelos'>Cabelos</a></li><li class='sub-nav-item'><a href='/corpo-e-banho/42/01' class='sub-nav-link' title='Corpo e Banho'>Corpo e Banho</a></li><li class='sub-nav-item'><a href='/cuidados-femininos/44/01' class='sub-nav-link' title='Cuidados Femininos'>Cuidados Femininos</a></li><li class='sub-nav-item'><a href='/cuidados-masculinos/49/01' class='sub-nav-link' title='Cuidados Masculinos'>Cuidados Masculinos</a></li><li class='sub-nav-item'><a href='/maos-e-pes/53/01' class='sub-nav-link' title='Mãos e Pés'>Mãos e Pés</a></li><li class='sub-nav-item'><a href='/maquiagem/54/01' class='sub-nav-link' title='Maquiagem'>Maquiagem</a></li><li class='sub-nav-item'><a href='/nutricosmeticos/56/01' class='sub-nav-link' title='Nutricosméticos'>Nutricosméticos</a></li><li class='sub-nav-item'><a href='/colonias/59/01' class='sub-nav-link' title='Colônias'>Colônias</a></li><li class='sub-nav-item'><a href='/tratamento-do-corpo/64/01' class='sub-nav-link' title='Tratamento do Corpo'>Tratamento do Corpo</a></li><li class='sub-nav-item'><a href='/higiene-bucal/68/01' class='sub-nav-link' title='Higiene Bucal'>Higiene Bucal</a></li><li class='sub-nav-item'><a href='/protecao-solar/69/01' class='sub-nav-link' title='Proteção Solar'>Proteção Solar</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="banner_menu_p2"> <img id="banner_menu_img2" /></a>
                                                     </div>
                                            </div>
                                        </li>
                                        <li class="nav-item mamae-e-bebe"><a href='https://www.onofre.com.br' title='Mamãe e Bebê' class='nav-link'>Mamãe e Bebê</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class='sub-nav-item'><a href='/acessorios-infantis/37/01' class='sub-nav-link' title='Acessórios Infantis'>Acessórios Infantis</a></li><li class='sub-nav-item'><a href='/alimentos-infantis/38/01' class='sub-nav-link' title='Alimentos Infantis'>Alimentos Infantis</a></li><li class='sub-nav-item'><a href='/corpo-e-banho-infantil/41/01' class='sub-nav-link' title='Corpo e Banho Infantil'>Corpo e Banho Infantil</a></li><li class='sub-nav-item'><a href='/cuidados-com-a-mamae/43/01' class='sub-nav-link' title='Cuidados com a Mamãe'>Cuidados com a Mamãe</a></li><li class='sub-nav-item'><a href='/troca-de-fraldas/45/01' class='sub-nav-link' title='Troca de Fraldas'>Troca de Fraldas</a></li><li class='sub-nav-item'><a href='/cuidado-bucal-infantil/47/01' class='sub-nav-link' title='Cuidado Bucal Infantil'>Cuidado Bucal Infantil</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="banner_menu_p3"> <img id="banner_menu_img3" /></a>
                                                     </div>
                                            </div>
                                        </li>
                                        <li class="nav-item ofertas-e-lancamentos"><a href='https://www.onofre.com.br' title ='Ofertas e Lançamentos' class='nav-link'>&nbsp&nbsp Ofertas e &nbsp&nbsp&nbsp&nbsp&nbsp<br /> &nbsp&nbsp Lançamentos</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/oferta/66" class="sub-nav-link" title="Ofertas">Ofertas</a></li>
                                                </ul>
                                                <ul class="sub-nav-col">
                                                    <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/lancamento/66" class="sub-nav-link" title="Lançamentos">Lançamentos</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="banner_menu_p4"> <img id="banner_menu_img4" /></a>
                                                     </div>
                                            </div>
                                        </li>
                                        <li class="nav-item como-comprar"><a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=251' title='Como Comprar' class='nav-link'>Como Comprar</a></li>
                                    </ul>
                                </div>
                            </nav>
        <div class="float-bar"></div>
        
        <!-- /floatbar -->
        <!-- FIM HEADER -->
        <!-- ESTRUTURA -->
        <div class="page-content">
            <div class="wrapper">
                <!-- conteudo -->
                
    <script>
  window.fbAsyncInit = function() {
    FB.init({
      appId      : '333327017122265',
      xfbml      : true,
      version    : 'v2.8'
    });
    FB.AppEvents.logPageView();
  };
</script>
    <!-- Load Facebook SDK for JavaScript -->
    <div id="fb-root"></div>
    <script>(function(d, s, id) {
      var js, fjs = d.getElementsByTagName(s)[0];
      if (d.getElementById(id)) return;
      js = d.createElement(s); js.id = id;
      js.src = "https://connect.facebook.net/pt_BR/sdk.js#xfbml=1&version=v2.8";
      fjs.parentNode.insertBefore(js, fjs);
    }(document, 'script', 'facebook-jssdk'));</script>

    <div class="page-content">
        <div class="wrapper">
            <input type="hidden" name="ctl00$cphConteudo$url" id="url" />
            <input type="hidden" name="ctl00$cphConteudo$hdAtivo" id="hdAtivo" />
            <ul class="breadcrumb full">
                <div id="breadcrumbs">
                    <a href="/Default.aspx">Drogaria Onofre</a> &#62; <a href=/medicamentos/55/01 class="bread_beleza">Medicamentos</a> &#62; <a href=/medicamentos/antiarritmico/27/03 class="bread_beleza">Antiarritmico</a>

                </div>
            </ul>
            <div class="main-product-image col9">
                <div class="main-image-wrap">
                    <!-- SELO PRODUTO -->
                    <div id="cphConteudo_seloProduto" style="background:white;border-radius:5px;color:white;text-align:center;">selo produto</div>
                    <!-- FIM SELO PRODUTO -->
                    <a href="https://www.onofre.com.br/estatico/Produto/Super/" id="cphConteudo_linkimgGrande" class="jqzoom" rel="gal1" title="Cloridrato de Sotalol 160mg 30 Comprimidos - Merck - Genérico" alt="Cloridrato de Sotalol 160mg 30 Comprimidos - Merck - Genérico">
                        <img id="cphConteudo_imgGrande" alt="Cloridrato de Sotalol 160mg 30 Comprimidos - Merck - Genérico" src="https://www.onofre.com.br/img/Busca/imagem_prescricao.jpg" height="480" width="480" />
                    </a></div>
                <input type="hidden" name="ctl00$cphConteudo$hf_id_produto" id="cphConteudo_hf_id_produto" value="8052" />
                <div class="img-thumbs">
                    <ul class="thumbs-list">
                        
                    </ul>
                </div>
            </div>
            <div class="main-product-info col7">
                <div class="flags"><span class="flag entrega-4horas">
                    </span> <span class="flag uso-adulto">
                        </span> </div>
                <div class="top-infos">
                    
                    <span class="code col">
                        <span id="cphConteudo_lblCode">Cód: 121398</span></span> <span class="ms col">
                            <span id="cphConteudo_num_registro"> MS: 1008902810023</span></span> </div>
                <h1 class="main-product-name">
                    <input type="hidden" name="ctl00$cphConteudo$ProductId" id="cphConteudo_ProductId" value="8052" />
                    <span id="lblProductName">Cloridrato de Sotalol 160mg 30 Comprimidos - Merck - Genérico</span></h1>
                
                <span id="cphConteudo_produtoAntibioticoAviso"></span>
                <span id="cphConteudo_listaProdutoAntbiotico"></span>
                <div class="top-infos">
                    <span id="cphConteudo_lblProductManufacturer"><a class="fabricante2" href="">Merck</a></span>
                </div>
                <div class="product-spec">
                    <div id="DtlprinAtivo" class="spec principio-ativo">
                        <p class="spec-title col2">Princípio Ativo </p>
                        <p class="spec-text col5">
                            <span id="cphConteudo_lblDescriptionResume">Cloridrato de Sotalol</span>
                        </p>
                    </div>
                    
                    
                    
                    <a href="https://www.onofre.com.br/estatico/Bula/121398.pdf" id="bulaDetalhe" class="view-bula" target="_blank">Visualizar Bula do medicamento</a>
                    <div class="action-box">
                        
                        <div class="col3 dinheiro-extra" style="position: relative; margin-top: 10px;">
                            <div class="fb-save" data-uri="http://www.onofre.com.br/DetalheProduto/Default.aspx?ProductName=cloridrato-de-sotalol-160mg-30-comprimidos-merck-generico&ProductId=8052" data-size="small"></div>
                            
                            
                            <div id="cphConteudo_divSemPBM" style="margin-top: -10px;"><small class="aviso">Preço válido para compras feitas pela internet. Imagem meramente ilustrativa.</small>
                                <!-- Campo CRM para medicamentos -->
                                <div id="cphConteudo_divCRM">
                                    <span id="cphConteudo_lblCrm">Insira o CRM do Médico:</span>
                                    <input name="ctl00$cphConteudo$txtCrm" type="text" id="cphConteudo_txtCrm" style="width: 100px; padding-bottom: -110px;" />&nbsp;
                                    <select name="ctl00$cphConteudo$slCrmUF" id="cphConteudo_slCrmUF" onchange="ValidarSelectCRM(this)">
	<option selected="selected" value="SP" disabled="">UF</option>
	<option value="AC">AC</option>
	<option value="AL">AL</option>
	<option value="AP">AP</option>
	<option value="AM">AM</option>
	<option value="BA">BA</option>
	<option value="CE">CE</option>
	<option value="DF">DF</option>
	<option value="ES">ES</option>
	<option value="GO">GO</option>
	<option value="MA">MA</option>
	<option value="MS">MS</option>
	<option value="MT">MT</option>
	<option value="MG">MG</option>
	<option value="PA">PA</option>
	<option value="PB">PB</option>
	<option value="PR">PR</option>
	<option value="PE">PE</option>
	<option value="PI">PI</option>
	<option value="RJ">RJ</option>
	<option value="RN">RN</option>
	<option value="RS">RS</option>
	<option value="RO">RO</option>
	<option value="RR">RR</option>
	<option value="SC">SC</option>
	<option value="SP">SP</option>
	<option value="SE">SE</option>
	<option value="TO">TO</option>
</select>
                                </div>
                                <!-- Fim Campo CRM para Medicamentos -->
                                <em>
                                    <span id="cphConteudo_lblMsg">Venda sob prescrição médica.</span></em> </div>

                            
                            <div id="divDescricaoDermaClub" onclick="$(this).hide();" style="width: 100%; height: 100%; position: fixed; top: 0; left: 0; background-color: rgba(255,255,255,0.6); padding-top: 10%; display: none; z-index: 5">
                                <div style="background-color: #99CCFF; border: 2px dashed #00B0F0; width: 500px; height: 250px; margin: 0 auto; color: white; font-weight: bold; z-index: 5; font-size: 19px; padding-top: 10px;"><span style="margin: 0 auto; width: 95%; display: block;">"O DermaClub é o clube de vantagens das marcas<br />
                                    La Roche-Posay, Vichy e SkinCeuticals, onde você pode acumular pontos em todas as suas compras e trocar por descontos e benefícios exclusivos. Além disso, você recebe dicas personalizadas sobre sua pele dos maiores dermatologistas do Brasil. Junte-se a nós e aproveite o máximo de vantagens para você e sua pele. Cadastre-se em <a style="text-decoration: none; color: white;" target="_blank" href="https://www.dermaclub.com.br">www.dermaclub.com.br</a>" </span></div>
                            </div>
                            <!--<div id="cphConteudo_divSeloDermaclu" onclick="window.open(&#39;/loginloreal.aspx&#39;,&#39;_self&#39;);" style="width: 225px; height: 115px; background-color: #FF7C80; padding-left: 4px; padding-right: 4px; padding-top: 4px; position: absolute; left: -65px; margin-top: 50px;">
                                <div style="background-color: white; width: 217px; height: 75px;">
                                    <div style="margin: 0 auto; width: 65%; padding-top: 12px;">
                                        <img style="float: left; margin-right: 4px;" alt="Promoção" height="24" src="/~/img/DetalheProduto/icone-medalha.png" />
                                        <img style="float: left; margin-right: 4px;" alt="DermaClub" height="13" src="/~/img/DetalheProduto/dermaclub-logo.png" />
                                        <div onmouseover="$('#divDescricaoDermaClub').show();" style="float: left; font-size: 10px; color: white; font-weight: 600; width: 12px; height: 12px; background-image: url('/~/img/DetalheProduto/interrogation-mark.png'); background-size: cover;"></div>
                                        <div style="float: left; font-size: 7px; font-weight: 800">COMPRE & GANHE <span style="color: #5EB1D9">0 PONTOS</span></div>
                                    </div>
                                    <p align="center" style="font-family: Arial; font-weight: 900; color: black; font-size: 12px; padding-top: 15px;">Comprar com desconto</p>
                                </div>
                                <p id="cphConteudo_pDescontoPorcentagemDermaclub" align="center" style="color: white; font-weight: bold; font-size: 25px;"></p>
                            </div>-->

                            

                        </div>

                         
                        <div id="cphConteudo_divBuyArea" class="col4 buy-area">
                            <div id="cphConteudo_divDropQuantidade"><span class="group-title">Selecione a
                                <span id="cphConteudo_lblDescEspeci">Quantidade</span>:</span>
                                <div class="sku-radio"><span class="group-name">
                                    <span id="cphConteudo_lblDescEspeci1">Quantidade</span></span>
                                    <div class="sku-list">
                                        <ul>
                                            
                                                    <li class="sku-item"><a href="/cloridrato-de-sotalol-160mg-30-comprimidos-merck-generico/8052/05" id="Urlfilhos"> 
                                                        <label class="sku-name" for="beach"> 
                                                            <img id="cphConteudo_rptProdutoFilhos_imgEspe_0" Border="0" src="https://www.onofre.com.br/estatico/produto/especificacao/410.jpg" height="40" width="40" />
                                                            <span>30 comprimidos</span> </label>
                                                    </a></li>
                                                
                                        </ul>
                                    </div>
                                </div>
                            </div>
                            
                            <div id="cphConteudo_main_product" class="main-product-price"><span>
                                <label></label>
                            </span><span id="cphConteudo_old_price_span" class="old-price"><em>
                                <span id="cphConteudo_lblPrecoDe">R$ 67,55</span></em></span>  <span class="regular-price">
                                    <span id="cphConteudo_lblPrecoPor">R$ 35,80</span></span> </div>
                            <div id="cphConteudo_divComprar" class="buy-product buy-page">
                                <div id="cphConteudo_botao_quantidade_antigo" class="qtd">
                                    <div class="controls"><span onclick="incrementValue()">+</span> <span onclick="DecrementValue()">-</span> </div>
                                    <input name="ctl00$cphConteudo$txt_QtdDP" type="text" id="txt_QtdDP" value="1" class="qtd-field" readonly="readonly" />
                                </div>
                                <a href="javascript:chamarAjaxQtd('AddItem','[{idProduct:8052}]',parent.document.getElementById('txt_QtdDP').value);" id="cphConteudo_btComprarDP" class="btn-green btn-buy" onclick="SalvarCRMProduto">Comprar</a> </div>

                               <!--Quando o produto for derma club vai mostra um banner
                                <div style="top: 49%;left: 50%;margin-left: -25px;margin-top: 4px">
                                 <br />
                                         
                                 <a href="/loginloreal.aspx">
                                   <img id="derma-detalhe" style="display:none"   class="img-responsive" alt="derma club" src="../../img/DetalheProduto/dermaclub-detalhe.png"/>
                                  </a>
                                </div>  
                            -->
                               <!--*******************************************************************************-->


                            
                            
                            
                        </div>
                        <div>



 
                            
                        </div>
                        
                        

                        

                    </div>
                </div>
            </div>
            <div class="complementary row">
                
                <div id="AnvisaEtiquetaTextoSemBorda" class="generic col12">
                    
                    <div id="somebordamsgavisa" class="shelf-generic column3">
                        <p>
                            <span id="lblAnvisaEtiquetaDesc">CLORIDRATO DE SOTALOL 160MG 30 COMPRIMIDOS - MERCK - GENÉRICO É UM MEDICAMENTO, SEU USO PODE TRAZER RISCOS. PROCURE O MÉDICO E O FARMACÉUTICO. LEIA A BULA.</span>
                        </p>
                        <p id="AnvisaEtiquetaMensRED" class="color-preto">
                            <span id="lblAnvisaEtiquetaMens">VENDA SOB PRESCRIÇÃO MÉDICA.</span>
                        </p>
                    </div>
                </div>







                   </div>
            <div class="ch_clear" chaordic="top"></div>
            <div class="product-details tabs row col12">
                <nav class="tab-nav">
                    
                    <h2 id="cphConteudo_divDescricao_tab" class="tab-item active" data-item="descricao">Descrição do Produto</h2>
                    
                    
                </nav>
                
                <div id="cphConteudo_divDescricao" class="tab-content descricao active">
                    <p>
                        <!-- saved from url=(0022)http://internet.e-mail -->
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
	<META HTTP-EQUIV="CONTENT-TYPE" CONTENT="text/html; charset=iso-8859-1">
	<TITLE></TITLE>
	<META NAME="GENERATOR" CONTENT="StarOffice/5.2 (Win32)">
	<META NAME="AUTHOR" CONTENT=" ">
	<META NAME="CREATED" CONTENT="20020924;13270713">
	<META NAME="CHANGEDBY" CONTENT=" ">
	<META NAME="CHANGED" CONTENT="20020924;14521735">
</HEAD>
<BODY>
<P ALIGN=LEFT STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Cloridrato
de Sotalol</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Medicamento
gen&eacute;rico Lei n&ordm; 9.787/99</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Forma
farmac&ecirc;utica e apresenta&ccedil;&atilde;o</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Cloridrato
de Sotalol 160 mg - Embalagem contendo 30 comprimidos.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>
</FONT></FONT><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Uso
oral - adulto</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Composi&ccedil;&atilde;o</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Cada
comprimido cont&eacute;m: </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Cloridrato
de Sotalol 
............................................................. 160 mg</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>e
excipientes (&aacute;cido este&aacute;rico, amido, celulose
microcristalina, di&oacute;xido de sil&iacute;cio, estearato de
magn&eacute;sio, lactose e corante azul).</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>
</FONT></FONT><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Informa&ccedil;&atilde;o
ao paciente</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>A&ccedil;&atilde;o
esperada do medicamento</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
produto &eacute; indicado no tratamento de arritmias card&iacute;acas.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Cuidados
de armazenamento</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Conservar
as embalagens do produto &agrave; temperatura ambiente (entre 15&deg;C
e 30&deg;C).</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Prazo
de validade</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
produto &eacute; v&aacute;lido por dois anos a partir da data de
fabrica&ccedil;&atilde;o impressa na embalagem. N&atilde;o use
medicamentos com prazo de validade vencido, pode ser perigoso para
sua sa&uacute;de.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Gravidez
e lacta&ccedil;&atilde;o</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Informe
seu m&eacute;dico a ocorr&ecirc;ncia de gravidez na vig&ecirc;ncia do
tratamento ou ap&oacute;s o seu t&eacute;rmino. Informar ao m&eacute;dico
se est&aacute; amamentando.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Cuidados
de administra&ccedil;&atilde;o</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Siga
a orienta&ccedil;&atilde;o do seu m&eacute;dico, respeitando sempre
os hor&aacute;rios, as doses e a dura&ccedil;&atilde;o do tratamento.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Tomar
o medicamento preferencialmente antes das refei&ccedil;&otilde;es.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Interrup&ccedil;&atilde;o
do tratamento</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>N&atilde;o
interromper o tratamento sem o conhecimento de seu m&eacute;dico.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Rea&ccedil;&otilde;es
adversas</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>As
rea&ccedil;&otilde;es mais comumente relatadas s&atilde;o dispn&eacute;ia,
fadiga, cefal&eacute;ia, bradicardia excessiva e hipotens&atilde;o.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Informe
seu m&eacute;dico do aparecimento de rea&ccedil;&otilde;es
desagrad&aacute;veis.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>-
Todo medicamento deve ser mantido fora do alcance das crian&ccedil;as.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Ingest&atilde;o
concomitante com outras subst&acirc;ncias</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Os
alimentos podem interferir na a&ccedil;&atilde;o do produto, por isso
deve-se tom&aacute;-lo antes das refei&ccedil;&otilde;es.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Contra-indica&ccedil;&otilde;es
e Precau&ccedil;&otilde;es</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
produto &eacute; contra-indicado para pacientes com asma br&ocirc;nquica,
choque cardiog&ecirc;nico, insufici&ecirc;ncia ventricular direita
devido a hipertens&atilde;o pulmonar, bradicardia acentuada, bloqueio
atrioventricular do 2&deg; grau ou total, insufici&ecirc;ncia
card&iacute;aca congestiva ou insufici&ecirc;ncia renal grave. A
seguran&ccedil;a e efic&aacute;cia do produto em crian&ccedil;as
abaixo de 18 anos n&atilde;o foi estabelecida.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>-	N&atilde;o
tome rem&eacute;dio sem o conhecimento do seu m&eacute;dico. Pode ser
perigoso para sua sa&uacute;de.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Informa&ccedil;&atilde;o
t&eacute;cnica</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Caracter&iacute;sticas</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
produto, uma mistura rac&ecirc;mica de d- e l-Cloridrato de Sotalol,
&eacute; um agente  bloqueador de receptor beta-adren&eacute;rgico
n&atilde;o seletivo, agindo nos receptores beta-1 e beta-2,
destitu&iacute;do de atividade simpatomim&eacute;tica intr&iacute;nseca
(ISA) e atividade estabilizadora de membrana (MSA). O Cloridrato de
Sotalol inibe a libera&ccedil;&atilde;o de renina. Sua atividade
beta-bloqueadora causa uma redu&ccedil;&atilde;o na freq&uuml;&ecirc;ncia
card&iacute;aca (efeito cronotr&oacute;pico negativo) e uma limitada
redu&ccedil;&atilde;o na for&ccedil;a de contra&ccedil;&atilde;o
(efeito inotr&oacute;pico negativo). Estas altera&ccedil;&otilde;es
no cora&ccedil;&atilde;o reduzem o consumo de oxig&ecirc;nio no
mioc&aacute;rdio e o trabalho card&iacute;aco.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
Cloridrato de Sotalol tem propriedades anti-arr&iacute;tmicas de
bloqueio do receptor beta-adren&eacute;rgico (classe II de Vaughan
Willians) e de prolongamento da dura&ccedil;&atilde;o do potencial de
a&ccedil;&atilde;o card&iacute;aco (classe III  de Vaughan Willians).</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>As
propriedades classe II e III podem ser refletidas no
eletrocardiograma pelo prolongamento dos intervalos PR, QT e QTc
(intervalo QT corrigido pela freq&uuml;&ecirc;ncia card&iacute;aca)
sem altera&ccedil;&atilde;o significante na dura&ccedil;&atilde;o do
intervalo QRS.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Os
is&ocirc;meros d- e l- do Cloridrato de Sotalol t&ecirc;m efeitos
anti-arr&iacute;tmicos similares, embora o l-is&ocirc;mero seja
virtualmente o respons&aacute;vel por toda a atividade
beta-bloqueadora. Embora possa ocorrer um betabloqueio significativo
com doses orais baixas como 25 mg, os efeitos classe III s&atilde;o,
em geral, observados com doses di&aacute;rias maiores de 160 mg. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>N&iacute;veis
de pico s&atilde;o alcan&ccedil;ados em 2,5 a 4 horas e n&iacute;veis
plasm&aacute;ticos em estado de equil&iacute;brio s&atilde;o
atingidos em 2 a 3 dias. A absor&ccedil;&atilde;o &eacute; reduzida
em aproximadamente 20%, quando administrado com uma refei&ccedil;&atilde;o
padr&atilde;o, em compara&ccedil;&atilde;o &agrave;s condi&ccedil;&otilde;es
de jejum.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
Cloridrato de Sotalol n&atilde;o se liga &agrave;s prote&iacute;nas
plasm&aacute;ticas e n&atilde;o &eacute; metabolizado. A principal
via de elimina&ccedil;&atilde;o &eacute; a renal. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Aproximadamente
80 a 90% da dose &eacute; eliminada na urina de forma inalterada,
enquanto que o restante &eacute; eliminado nas fezes. Doses mais
baixas s&atilde;o necess&aacute;rias em condi&ccedil;&otilde;es de
comprometimento renal (ver Precau&ccedil;&otilde;es e Advert&ecirc;ncias).
A idade n&atilde;o altera significantemente a farmacocin&eacute;tica,
embora a fun&ccedil;&atilde;o renal comprometida em pacientes
geri&aacute;tricos possa diminuir  o &iacute;ndice de elimina&ccedil;&atilde;o,
resultando em aumento do ac&uacute;mulo da droga.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
Cloridrato de Sotalol produz redu&ccedil;&otilde;es consistentes no
batimento e pot&ecirc;ncia card&iacute;aca, sem redu&ccedil;&atilde;o
no volume sist&oacute;lico. Causa pouca ou nenhuma altera&ccedil;&atilde;o
na press&atilde;o sang&uuml;&iacute;nea sist&ecirc;mica em
normotensos, e n&atilde;o foi notada altera&ccedil;&atilde;o
significante na press&atilde;o arterial pulmonar. Em pacientes
hipertensos, o Cloridrato de Sotalol produz redu&ccedil;&otilde;es
significantes nas press&otilde;es sist&oacute;lica e diast&oacute;lica.
Embora o Cloridrato de Sotalol seja geralmente bem tolerado
hemodinamicamente, deve-se usar de cautela em pacientes com reserva
card&iacute;aca lim&iacute;trofe, visto que pode ocorrer deteriora&ccedil;&atilde;o
na fun&ccedil;&atilde;o card&iacute;aca.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>No
homem, os efeitos eletrofisiol&oacute;gicos (betabloqueio) de classe
II do Cloridrato de Sotalol se manifestam atrav&eacute;s do aumento
da dura&ccedil;&atilde;o do ciclo sinusal (frequ&ecirc;ncia card&iacute;aca
lenta-bradicardia), diminui&ccedil;&atilde;o da condu&ccedil;&atilde;o
nodal atrioventricular e aumento da refratariedade nodal
atrioventricular. Os efeitos eletrofisiol&oacute;gicos de classe IIl
incluem prolongamentos dos potenciais de a&ccedil;&atilde;o
monof&aacute;sico atrial e ventricular e prolongamento do per&iacute;odo
refrat&aacute;rio efetivo dos m&uacute;sculos atrial, ventricular e
da via complementar atrioventricular (onde houver) nas dire&ccedil;&otilde;es
anti-retr&oacute;gada e retr&oacute;gada. Com doses orais de 160 a
640 mg/dia, o eletrocardiograma pode mostrar aumentos m&eacute;dios
relacionados a dose de 40 a 100 mseg no intervalo QT e 10 a 40 mseg
no intervalo QTc (ver Precau&ccedil;&otilde;es e Advert&ecirc;ncias).
N&atilde;o foi observada nenhuma altera&ccedil;&atilde;o
significativa no intervalo QRS. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Estudos
cl&iacute;nicos - O estudo ESVEM (Estudo de Monitoriza&ccedil;&atilde;o
Eletrofisiol&oacute;gica versus Monitoriza&ccedil;&atilde;o
Elefrocardiogr&aacute;fica) foi elaborado para comparar a escolha da
terapia antiarr&iacute;tmica (sotalol, procainamida, quinidina,
mexiletina, propafenona, imipramina e pirmenol) atrav&eacute;s da
supress&atilde;o da estimula&ccedil;&atilde;o el&eacute;trica
programada (PES) contra pacientes selecionados pela monitoriza&ccedil;&atilde;o
por Holter, com hist&oacute;ria de taquicardia ventricular sustentada
(TV)/fibrila&ccedil;&atilde;o ventricular (FV), cuja TV/FV tamb&eacute;m
foram induzidas pelo PES e CVP (Contra&ccedil;&atilde;o Ventricular
Prematura) de 10 batimentos/hora registrado pela monitoriza&ccedil;&atilde;o
do Holter. A resposta aguda global, limitada &agrave; primeira droga
randomizada, foi 39% para o sotalol e 30% para as outras drogas
juntas. O &iacute;ndice de resposta aguda para a primeira droga
randomizada, usando a supress&atilde;o da indu&ccedil;&atilde;o do
PES, foi de 36% para o sotalol contra uma m&eacute;dia de 13% para as
outras drogas juntas. Usando os resultados da monitoriza&ccedil;&atilde;o
por Holter, o sotalol obteve 41% de resposta contra 45% para as
outras drogas combinadas. Entre aqueles que responderam &agrave;
terapia de longo prazo o sotalol foi identificado, de forma marcante,
como eficaz quando comparado &agrave;s outras drogas juntas, obtendo
a mais baixa mortalidade de 2 anos (13% contra 22%), o mais baixo
&iacute;ndice de recorr&ecirc;ncia de taquicardia ventricular de dois
anos (30% contra 60%) e o mais baixo &iacute;ndice de descontamina&ccedil;&atilde;o
(38% contra 75 a 80%). As doses de sotalol mais comumente usadas
foram 320 a 480 mg/dia (66% dos pacientes), com 16% recebendo &lt;
240 mg/dia e 18% recebendo &gt; 640 mg/dia.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Indica&ccedil;&otilde;es</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
Cloridrato de Sotalol &eacute; indicado no tratamento de:</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>1.
Arritmias </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Tratamento
de taquiarritmia ventricular grave. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Taquiarritmia
ventricular n&atilde;o-sustentada sintom&aacute;tica e contra&ccedil;&otilde;es
ventriculares prematuras sintom&aacute;ticas. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Tratamento
profil&aacute;tico da taquicardia atrial parox&iacute;stica,
fibrila&ccedil;&atilde;o atrial parox&iacute;stica, taquicardia
parox&iacute;stica do n&oacute; atrioventricular reentrante,
taquicardia parox&iacute;stica reentrante usando os sistemas de
condu&ccedil;&atilde;o atrioventricular e taquicardia
supraventricular parox&iacute;stica ap&oacute;s cirurgia card&iacute;aca.
</FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Manuten&ccedil;&atilde;o
do ritmo sinusal normal ap&oacute;s a convers&atilde;o da fibrila&ccedil;&atilde;o
ou flutter atrial. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Controle
do &iacute;ndice ventricular em pacientes com fibrila&ccedil;&atilde;o
atrial cr&ocirc;nica ou flutter atrial. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Arritmias
causadas por excesso de catecolaminas circulantes e aquelas devido ao
aumento da sensibilidade &agrave;s catecolaminas. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Nenhuma
droga antiarr&iacute;tmica tem demonstrado reduzir a incid&ecirc;ncia
de morte s&uacute;bita em pacientes com arritmias supraventriculares
ou ventriculares assintom&aacute;ticas. Uma vez que a maioria das
drogas antiarr&iacute;tmicas t&ecirc;m potencial para causar
pr&oacute;-arritmias ou aumentar a incid&ecirc;ncia de morte s&uacute;bita,
os m&eacute;dicos devem considerar cautelosamente os riscos e os
benef&iacute;cios da terapia antiarr&iacute;tmica nestes pacientes. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>2.
Angina Pectoris </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
Cloridrato de Sotalol reduz a incid&ecirc;ncia e severidade dos
ataques de angina e aumenta a toler&acirc;ncia ao exerc&iacute;cio.
Pode ser usado em todos os casos de angina pectoris, incluindo casos
severos e intrat&aacute;veis. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>3.
P&oacute;s-Infarto do Mioc&aacute;rdio </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
Cloridrato de Sotalol, quando administrado dentro de 5 a 14 dias do
infarto agudo do mioc&aacute;rdio, produz uma significante redu&ccedil;&atilde;o
no &iacute;ndice de reinfarto, e uma tend&ecirc;ncia de mortalidade
mais baixa durante o ano ap&oacute;s o infarto (ver Precau&ccedil;&otilde;es
e Advert&ecirc;ncias -Infarto do mioc&aacute;rdio recente).</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Contra-indica&ccedil;&otilde;es</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
produto &eacute; contra-indicado em pacientes com: </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Asma
br&ocirc;nquica ou doen&ccedil;a obstrutiva cr&ocirc;nica das vias
a&eacute;reas; </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Hipersensibilidade
pr&eacute;via ao produto; </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Choque
cardiog&ecirc;nico; </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Anestesia
que produza depress&atilde;o do mioc&aacute;rdio-bradicardia sinusal
sintom&aacute;tica;</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>S&iacute;ndrome
da doen&ccedil;a sinusal, bloqueio atrioventricular de segundo e
terceiro graus, a menos que esteja usando um marca-passo; </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Insufici&ecirc;ncia
card&iacute;aca congestiva n&atilde;o controlada;</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Insufici&ecirc;ncia
renal; </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>S&iacute;ndrome
do QT longo cong&ecirc;nita ou adquirida.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Precau&ccedil;&otilde;es
e Advert&ecirc;ncias</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Anestesia
- Recomenda-se cuidado com o uso de agentes bloqueadores do receptor
beta-adren&eacute;rgico, incluindo o Cloridrato de Sotalol, em
pacientes submetidos a cirurgia e em associa&ccedil;&atilde;o com
anest&eacute;sicos que causem depress&atilde;o do mioc&aacute;rdio,
tais como ciclopropano e tricloroetileno. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Diabetes
- Em pacientes com diabete (especialmente diabete inst&aacute;vel) ou
com hist&oacute;ria de epis&oacute;dios de hipoglicemia espont&acirc;nea,
o medicamento deve ser administrado com cautela, uma vez que o
beta-bloqueador pode mascarar alguns sinais iniciais importantes de
hipoglicemia aguda, como por exemplo taquicardia. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Tireotoxicose
- Os beta-bloqueadores podem mascarar certos sinais cl&iacute;nicos
(ex. taquicardia) de hipertireoidismo. Pacientes com suspeita de
desenvolvimento de tireotoxicose devem ser tratados cuidadosamente
para evitar uma retirada repentina do beta-bloqueador. Esta pode ser
seguida por um agravamento dos sintomas de hipertireoidismo,
incluindo dist&uacute;rbios da tire&oacute;ide. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Comprometimento
hep&aacute;tico - uma vez que o produto n&atilde;o est&aacute;
sujeito ao metabolismo de primeira passagem, os pacientes com
comprometimento hep&aacute;tico n&atilde;o demonstraram altera&ccedil;&atilde;o
no clearance. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Comprometimento
renal: O produto &eacute; eliminado principalmente por via renal,
atrav&eacute;s de filtra&ccedil;&atilde;o glomerular e, em menor
grau, por secre&ccedil;&atilde;o tubular. H&aacute; um relacionamento
direto entre a fun&ccedil;&atilde;o renal, medida pela creatinina
s&eacute;rica ou pelo &quot;clearance&quot; de creatinina, e a
meia-vida de elimina&ccedil;&atilde;o do produto e sua excre&ccedil;&atilde;o
urin&aacute;ria. Um guia para dosagem em condi&ccedil;&otilde;es de
comprometimento renal &eacute; apresentado no item &quot;Posologia&quot;.
</FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Psor&iacute;ase
- drogas beta-bloqueadoras raramente t&ecirc;m sido relatadas por
aumentar os sintomas de psor&iacute;ase vulgar.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Pr&oacute;-arritmia
- O efeito adverso mais perigoso das drogas antiarr&iacute;tmicas &eacute;
o agravamento das arritmias pr&eacute;-existentes ou a indu&ccedil;&atilde;o
de novas arritmias. As drogas que prolongam o intervalo QT podem
causar &quot;Torsade de Pointes&quot;, uma taquicardia ventricular
polim&oacute;rfica associada ao prolongamento do intervalo QT. A
experi&ecirc;ncia at&eacute; o momento indica que o risco de &quot;Torsade
de Pointes&quot; est&aacute; associado com o prolongamento do
intervalo QT, redu&ccedil;&atilde;o da frequ&ecirc;ncia card&iacute;aca,
redu&ccedil;&atilde;o do pot&aacute;ssio e magn&eacute;sio s&eacute;rico
(por ex., como consequ&ecirc;ncia do uso de diur&eacute;tico), altas
concentra&ccedil;&otilde;es de droga no plasma (por ex., como
consequ&ecirc;ncia de superdosagem ou insufici&ecirc;ncia renal) e
com o uso concomitante de sotalol e outras medica&ccedil;&otilde;es,
tais como anti-depressivos e antiarr&iacute;tmicos de classe I, que
foram associados ao &quot;Torsade de Pointes&quot;. Mulheres parecem
ter o risco de desenvolvimento de &quot;Torsade de Pointes&quot;
aumentado.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Monitoriza&ccedil;&atilde;o
do eletrocardiograma imediatamente antes ou ap&oacute;s o epis&oacute;dio
geralmente revela intervalos QT e QTc prolongados. Nos estudos
cl&iacute;nicos o produto, em geral, n&atilde;o tem sido iniciado em
pacientes cujo intervalo QTc do pr&eacute;-tratamento tenha excedido
450 mseg. O Cloridrato de Sotalol deve ser titulado muito
cautelosamente em pacientes com intervalos QT prolongados. O &quot;Torsade
de Pointes&quot; &eacute; dependente da dose e, em geral ocorre
precocemente ap&oacute;s o in&iacute;cio da terapia ou no
escalonamento da dose e termina de forma espont&acirc;nea na maioria
dos pacientes. Embora a maioria dos epis&oacute;dios de &quot;Torsade
de Pointes&quot; seja autolimitada ou associada a sintomas (por ex.
s&iacute;ncope), eles podem progredir para fibrila&ccedil;&atilde;o
ventricular. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Durante
os estudos cl&iacute;nicos, 4,3% dos 3257 pacientes com arritmias
experimentaram um epis&oacute;dio piorado ou novo de arritmia
ventricular, incluindo taquicardia ventricular sustentada
(aproximadamente 1%) e &quot;Torsade de Pointes&quot;(2,4%). Al&eacute;m
disso, em aproximadamente 1% dos pacientes, as mortes foram
consideradas possivelmente relacionadas &agrave; droga. Em pacientes
com outras arritmias ventriculares e supraventriculares menos s&eacute;rias,
a incid&ecirc;ncia de &quot;Torsade de Pointes&quot; foi 1% e 1,4%
respectivamente. Pr&oacute;-arritmias graves incluindo &quot;Torsade
de Pointes&quot; estavam relacionadas com a dose como indicado
abaixo: </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>PERCENTAGEM
DE INCID&Ecirc;NCIA DE PR&Oacute;-ARRITMIAS GRAVES, DE ACORDO COM A
DOSE, EM PACIENTES COM TV/FV </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>dose
di&aacute;ria (mg) 		incid&ecirc;ncia de pr&oacute;-arritmias graves*
		pacientes 	</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>1
-80 						0 					0/72</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>81-
160					0,5%					4/838 </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>161-320
					1,8% 					17/960 </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>321-480
					4,5% 					21/471 </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>481-640
					4,8% 					15/327 </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>&gt;
640 						6,8%					7/103 ' </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>*
&quot;Torsade de Pointes&quot; ou Novas TV /FV Sustentada</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Outros
fatores de risco para &quot;Torsade de Pointes&quot; foram o
prolongamento excessivo do intervalo QTc e hist&oacute;ria de
cardiomegalia ou insufici&ecirc;ncia card&iacute;aca congestiva
(ICC). Os pacientes com taquicardia ventricular sustentada e hist&oacute;ria
de ICC tiveram um risco mais alto de pr&oacute;-arritmia grave
(aproximadamente 7%). Eventos pr&oacute;-arr&iacute;tmicos devem ser
esperados, n&atilde;o somente no in&iacute;cio da terapia, mas com
cada ajuste crescente de dose; os eventos tendem a ocorrer dentro de
7 dias do in&iacute;cio da terapia ou com um aumento da dose. Terapia
inicial com 80 mg duas vezes ao dia com aumento gradual em
conseq&uuml;&ecirc;ncia da titula&ccedil;&atilde;o da dose, reduz o
risco de pr&oacute;-arritmia (ver Posologia). O Cloridrato de Sotalol
deve ser usado com cautela caso o intervalo QTc seja maior que 500
mseg na terapia e deve-se considerar seriamente a redu&ccedil;&atilde;o
da dose ou descontinua&ccedil;&atilde;o de terapia, quando o
intervalo QT exceder 550 mseg. Devido aos m&uacute;ltiplos fatores de
risco associados com o &quot;Torsade de Pointes&quot;, contudo,
deve-se usar de cautela com rela&ccedil;&atilde;o ao intervalo QTc. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Retirada
repentina: observa-se hipersensibilidade &agrave;s catecolaminas nos
pacientes nos quais ocorreu a retirada da terapia com
beta-bloqueadores. Epis&oacute;dios ocasionais de agravamento da
angina pectoris, arritmias e, em alguns casos, infarto do mioc&aacute;rdio
foram reportados ap&oacute;s descontinua&ccedil;&atilde;o repentina
da terapia com beta-bloqueadores. Portanto, recomenda-se que
pacientes em uso cr&ocirc;nico de Cloridrato de Sotalol devem ser
cuidadosamente monitorizados quando da sua descontinua&ccedil;&atilde;o,
particularmente em pacientes com isquemia card&iacute;aca. Se
poss&iacute;vel a dosagem deve ser gradualmente reduzida em um
per&iacute;odo de uma a duas semanas. Em raz&atilde;o de a doen&ccedil;a
arterial coronariana ser comum e poder n&atilde;o ser reconhecida em
pacientes recebendo Cloridrato de Sotalol, a descontinua&ccedil;&atilde;o
repentina em pacientes com arritmias pode deixar percept&iacute;vel a
insufici&ecirc;ncia coronariana latente. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Insufici&ecirc;ncia
card&iacute;aca congestiva: O beta-bloqueio pode levar &agrave;
depress&atilde;o da contratilidade do mioc&aacute;rdio e precipitar
uma insufici&ecirc;ncia card&iacute;aca mais severa. Recomenda-se
cuidado quando do in&iacute;cio da terapia em pacientes com disfun&ccedil;&atilde;o
ventricular esquerda controlada pela terapia (por ex. inibidor da
ECA, diur&eacute;ticos, digit&aacute;licos, etc). Uma dose inicial
baixa e uma cuidadosa titula&ccedil;&atilde;o de dose s&atilde;o
convenientes. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Infarto
do mioc&aacute;rdio recente: Em pacientes p&oacute;s-infarto com
fun&ccedil;&atilde;o ventricular esquerda comprometida deve-se
considerar o risco e o benef&iacute;cio da administra&ccedil;&atilde;o
de sotalol. Uma cuidadosa monitoriza&ccedil;&atilde;o e titula&ccedil;&atilde;o
de dose s&atilde;o importantes durante o in&iacute;cio e no
acompanhamento da terapia. Os eventos adversos de estudos cl&iacute;nicos
envolvendo drogas antiarr&iacute;tmicas (isto &eacute;, aumento
aparente na mortalidade) sugerem que o Cloridrato de Sotalol deve ser
evitado em pacientes com fra&ccedil;&atilde;o de eje&ccedil;&atilde;o
do ventr&iacute;culo esquerdo &lt; 40% tratados com altas doses (640
mg/dia), houve ind&iacute;cios de um excesso sem arritmias
ventriculares s&eacute;rias. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Em
um extenso estudo controlado em pacientes com infarto do mioc&aacute;rdio
recente, sem insufici&ecirc;ncia card&iacute;aca, que n&atilde;o
tiveram necessariamente arritmias ventriculares, o tratamento com
Cloridrato de Sotalol oral foi associado com uma redu&ccedil;&atilde;o
estatisticamente n&atilde;o significativa do risco na mortalidade,
comparado ao grupo placebo (18%). Neste estudo p&oacute;s-infarto,
usando uma dose fixa de 320 mg uma vez ao dia e em um segundo estudo
randomizado, pequeno, em pacientes de alto risco p&oacute;s-
infartados, com fra&ccedil;&otilde;es de eje&ccedil;&atilde;o do
ventr&iacute;culo esquerdo &lt; 40%, tratados com altas doses (640
mg/dia), houve ind&iacute;cios de um excesso de mortes precoces
s&uacute;bitas. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Dist&uacute;rbios
eletrol&iacute;ticos: O Cloridrato de Sotalol n&atilde;o deve ser
usado em pacientes com hipocalemia ou hipomagnesemia, antes da
corre&ccedil;&atilde;o do desequil&iacute;brio; estas condi&ccedil;&otilde;es
podem agravar o grau de prolongamento do intervalo QT e aumentar o
potencial para &#147;Torsade de Pointes&#148;. Aten&ccedil;&atilde;o
especial deve ser dada para o balan&ccedil;o de eletr&oacute;litos e
&aacute;cido-b&aacute;sico em pacientes com diarr&eacute;ia severa e
prolongada ou pacientes recebendo concomitantemente drogas depletoras
de magn&eacute;sio e/ou pot&aacute;ssio.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>AItera&ccedil;&otilde;es
eletrocardiogr&aacute;ficas: Prolongamento excessivo do intarvalo QT
maior que 0,55 segundos pode ser um sinal de toxicidade e deve ser
evitado. Bradicardia sinusal (batimento card&iacute;aco menor que 50
batimentos por minuto) ocorreu com uma frequ&ecirc;ncia de 13% em
pacientes arr&iacute;tmicos recebendo Cloridrato de Sotalol nos
ensaios cl&iacute;nicos. A bradicardia por si s&oacute; aumenta o
risco de &#147;Torsade de Pointes&#148;. Pausa, parada e disfun&ccedil;&atilde;o
do n&oacute; sinusal ocorre em menos de 1% dos pacientes. A
incid&ecirc;ncia de bloqueio atrioventricular de 2&deg; ou 3&deg;
grau &eacute; de aproximadamente 1 %. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Anafilaxia:
pacientes com hist&oacute;ria de rea&ccedil;&atilde;o anafil&aacute;tica
para uma variedade de alergenos pode ter uma rea&ccedil;&atilde;o
mais severa com administra&ccedil;&otilde;es repetidas enquanto
recebendo beta-bloqueadores. Tais pacientes podem n&atilde;o
responder &agrave;s doses usuais de epinefrina usadas para o
tratamento de rea&ccedil;&otilde;es al&eacute;rgicas. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Intera&ccedil;&otilde;es
medicamentosas</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Antiarr&iacute;tmicos:
drogas antiarr&iacute;tmicas da classe IA, tais como disopiramida,
quinidina e procainamida e outras drogas da classe III (ex.
Amiodarona) n&atilde;o s&atilde;o recomendadas como terapia
concomitante com o Cloridrato de Sotalol devido ao seu potencial de
prolongar a refratariedade (ver Precau&ccedil;&otilde;es e
Advert&ecirc;ncias). O uso concomitante de outros agentes
beta-bloqueadores com o Cloridrato de Sotalol pode resultar em
efeitos aditivos classe II. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Diur&eacute;ticos
depletores de pot&aacute;ssio: hipocalemia ou hipomagnesemia podem
ocorrer, aumentando o potencial de &quot;Torsade de Pointes&quot;
(ver Precau&ccedil;&otilde;es e Advert&ecirc;ncias, dist&uacute;rbios
eletrol&iacute;ticos).</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Drogas
que prolongam o intervalo QT: O Cloridrato de Sotalol deve ser
administrado com extrema cautela em conjunto com outras drogas
conhecidas por prolongar o intervalo QT, tais como os agentes
antiarr&iacute;tmicos de classe I, fenotiazinas, anti-depressivos
tric&iacute;clicos, terfenadina e astemizol (ver Precau&ccedil;&otilde;es
e Advert&ecirc;ncias). </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Digoxina:
doses &uacute;nicas ou m&uacute;ltiplas de Cloridrato de Sotalol n&atilde;o
afetam significativamente os n&iacute;veis de digoxina. Eventos
pr&oacute;-arr&iacute;tmicos foram mais comuns nos pacientes tratados
com sotalol, tamb&eacute;m recebendo digoxina; no entanto, isto pode
estar relacionado &agrave; presen&ccedil;a de insufici&ecirc;ncia
card&iacute;aca congestiva, um conhecido fator de risco da
pr&oacute;-arritmia, no paciente recebendo digoxina. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Drogas
bloqueadoras de c&aacute;lcio: a administra&ccedil;&atilde;o
concomitante de agentes beta-bloqueadores e bloqueadores de canais de
c&aacute;lcio resultou em hipotens&atilde;o, bradicardia, dist&uacute;rbios
de condu&ccedil;&atilde;o e insufici&ecirc;ncia card&iacute;aca. Os
beta-bloqueadores devem ser evitados em associa&ccedil;&atilde;o com
bloqueadores dos canais de c&aacute;lcio cardiodepressores, tais como
verapamil e diltiazem, devido aos efeitos aditivos na condu&ccedil;&atilde;o
atrioventricular e na fun&ccedil;&atilde;o ventricular. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Agentes
depletores de catecolaminas: o uso concomitante de drogas depletoras
de catecolaminas, tais como reserpina e guanitidina, com um
beta-bloqueador pode produzir uma redu&ccedil;&atilde;o excessiva do
tonus nervoso simp&aacute;tico em repouso. Pacientes devem ser
estritamente monitorizados com rela&ccedil;&atilde;o a evid&ecirc;ncias
de hipotens&atilde;o e/ou bradicardia acentuada, os quais podem
produzir s&iacute;ncope. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Insulina
e hipoglicemiantes orais: pode ocorrer hiperglicemia e a dosagem da
droga anti-diab&eacute;tica pode necessitar de ajuste. Os sintomas de
hipoglicemia podem ser mascarados pelo Cloridrato de Sotalol.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Estimulantes
do receptor beta-2: os beta-agonistas tais como salbutamol,
terbutalina e isoprenalina podem ter suas dosagens aumentadas quando
usados concomitantemente com Cloridrato de Sotalol (ver
Contra-indica&ccedil;&otilde;es).</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Clonidina:
as drogas beta-bloqueadoras podem potencializar a hipertens&atilde;o
rebote, algumas vezes observada ap&oacute;s a descontinua&ccedil;&atilde;o
da clonidina; portanto, o beta-bloqueador deve ser vagarosamente
descontinuado v&aacute;rios dias antes da retirada gradual da
clonidina.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Gravidez-categoria
B: embora n&atilde;o haja estudos adequados e bem controlados na
gravidez, o Cloridrato de Sotalol demonstrou atravessar a placenta e
&eacute; encontrado no l&iacute;quido amni&oacute;tico. Portanto, o
produto deve usado durante a gravidez somente se o benef&iacute;cio
for maior que o risco. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Lactantes:
O Cloridrato de Sotalol &eacute; excretado no leite de animais de
laborat&oacute;rios e foi relatada sua presen&ccedil;a no humano.
Devido ao potencial de rea&ccedil;&otilde;es adversas do produto em
lactentes, na decis&atilde;o de se interromper a amamenta&ccedil;&atilde;o
ou de descontinuar a droga, deve-se levar em conta a import&acirc;ncia
da droga para a m&atilde;e .</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Uso
pedi&aacute;trico: a seguran&ccedil;a e efic&aacute;cia do Cloridrato
de Sotalol em crian&ccedil;as abaixo de 18 anos n&atilde;o foi
estabelecida.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Rea&ccedil;&otilde;es
adversas/colaterais e altera&ccedil;&otilde;es de exames
laboratoriais</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
Cloridrato de Sotalol &eacute; bem tolerado na maioria dos pacientes,
com os eventos adversos mais freq&uuml;entes originados de suas
propriedades beta-bloqueadoras. Os eventos adversos s&atilde;o
geralmente transit&oacute;rios e raramente necessitam de interrup&ccedil;&atilde;o
ou retirada do tratamento. Estes eventos incluem dispn&eacute;ia,
fadiga, tonturas, cefal&eacute;ia, febre, bradicardia excessiva e
(ou) hipotens&atilde;o. Caso ocorram, esses efeitos adversos
geralmente desaparecem quando a dose &eacute; reduzida. Os eventos
adversos mais significativos, no entanto, s&atilde;o aqueles devidos
&agrave; pr&oacute;-arritmia incluindo &#147;Torsade de Pointes&#148;.
</FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Uso
em arritmias: Nos estudos cl&iacute;nicos, 3.256 pacientes  com
arritmias card&iacute;acas (1.363 com taquicardia ventricular
sustentada) receberam o Cloridrato de Sotalol oral, dos quais 2.451
receberam a droga por pelo menos duas semanas. Os eventos adversos
mais significativos foram &#147;Torsade de Pointes&#148; e outras
novas arritmias ventriculares graves (ver Precau&ccedil;&otilde;es e
Advert&ecirc;ncias), as quais ocorreram nos seguintes &iacute;ndices:
</FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>POPULA&Ccedil;&Atilde;O
DE PACIENTES</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-left: 5cm; text-indent: 1.25cm; margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>TV/FV			TVNS/CVP			AVS</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>					n
= 1363		n=946			         n=947</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>&#147;Torsades
de Pointes&#148;		4,1%			1,0%				1,4%</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>TV/FV
sustentada			1,2%			0,7%				0,3%					</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>TV
= taquicardia ventricular</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>FV
= fibrila&ccedil;&atilde;o ventricular</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>TVNS
= taquicardia ventricular n&atilde;o sustentada</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>CVP
= contra&ccedil;&atilde;o ventricular prematura</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>ASV
= arritmia supraventricular</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>De
forma geral, a descontinua&ccedil;&atilde;o em raz&atilde;o de
eventos adversos intoler&aacute;veis foi necess&aacute;ria em 18% de
todos os pacientes nos estudos de arritmia card&iacute;aca. Os
eventos adversos mais comuns que levaram a uma descontinua&ccedil;&atilde;o
do Cloridrato de Sotalol foram: fadiga, 4%; bradicardia (&lt; 50
bpm), 3%; dispn&eacute;ia, 3%; pr&oacute;-arritmia, 2%; astenia, 2%;
e tonturas, 2%. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Os
eventos adversos a seguir s&atilde;o considerados relacionados &agrave;
terapia, ocorrendo em 1% ou mais dos pacientes tratados com o
Cloridrato de Sotalol. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Cardiovasculares:
bradicardia, dispn&eacute;ia, dor no peito, palpita&ccedil;&otilde;es,
edema, anormalidades no eletrocardiograma, hipotens&atilde;o,
pr&oacute;-arritmia, s&iacute;ncope, insufici&ecirc;ncia card&iacute;aca,
pr&eacute;-s&iacute;ncope. Dermatol&oacute;gicos: erup&ccedil;&atilde;o
cut&acirc;nea. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Gastrintestinais:
n&aacute;useas/v&ocirc;mitos, diarr&eacute;ia, dispepsia, dor
abdominal, flatul&ecirc;ncia. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Musculoesquel&eacute;ticos:
c&atilde;ibras. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Nervosos/psiqui&aacute;tricos:
fadiga, tontura, astenia, del&iacute;rio, cefal&eacute;ia, dist&uacute;rbios
do sono, depress&atilde;o, parestesia, altera&ccedil;&otilde;es do
humor, ansiedade. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Urogenitais:
disfun&ccedil;&atilde;o sexual. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Sentidos
especiais: dist&uacute;rbios visuais, anormalidades no paladar,
dist&uacute;rbios auditivos. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Org&acirc;nicos
gerais: febre. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>A
presen&ccedil;a de sotalol na urina pode resultar em n&iacute;veis
falso-positivos elevados de metanefrina quando medidos por m&eacute;todos
fotom&eacute;tricos. Pacientes com suspeita de feocromocitoma e que
s&atilde;o tratados com sotalol, devem ter sua urina analisada
atrav&eacute;s de cromatografia l&iacute;quida de alta press&atilde;o
com extra&ccedil;&atilde;o da fase s&oacute;lida.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Posologia</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
Cloridrato de Sotalol &eacute; administrado por via oral. Pacientes
apresentando bradicardia ou hipotens&atilde;o excessiva no in&iacute;cio
da administra&ccedil;&atilde;o do produto devem ter sua terapia
suspensa; o Cloridrato de Sotalol pode ser reintroduzido mais tarde
em doses mais baixas. Uma redu&ccedil;&atilde;o de dose pode tamb&eacute;m
ser recomend&aacute;vel para avaliar sintomas de fraqueza e tonturas
em casos quando a press&atilde;o arterial permanece baixa ap&oacute;s
mais de um m&ecirc;s de terapia. O Cloridrato de Sotalol &eacute;
administrado, preferencialmente, 1 a 2 horas antes das refei&ccedil;&otilde;es.
</FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Arritmias:
Como com outros agentes antiarr&iacute;tmicos, o Cloridrato de
Sotalol deve ser iniciado e ter suas doses aumentadas de acordo com a
capacidade de monitoriza&ccedil;&atilde;o e de avalia&ccedil;&atilde;o
do ritmo card&iacute;aco. A dose deve ser individualizada para cada
paciente com base na resposta terap&ecirc;utica e toler&acirc;ncia.
Eventos pr&oacute;-arr&iacute;tmicos podem ocorrer, n&atilde;o
somente no in&iacute;cio da terapia, mas tamb&eacute;m com cada
aumento durante o ajuste da dose. A dosagem de Cloridrato de Sotalol
deve ser ajustada gradualmente com 2 a 3 dias entre os aumentos de
dose a fim de se atingir o estado de equil&iacute;brio e continuar
monitorizando os intervalos QT. O ajuste gradual da dose ajudar&aacute;
a prevenir o uso de doses que sejam mais altas do que as necess&aacute;rias
para controlar a arritmia. O esquema de dosagem inicial recomendado &eacute;
160 mg/dia, administrados em duas doses divididas com intervalos de
aproximadamente 12 horas. Esta dose pode ser aumentada para 240 ou
320 mg/dia, se necess&aacute;rio, ap&oacute;s avalia&ccedil;&atilde;o
adequada. Na maioria dos pacientes, a resposta terap&ecirc;utica &eacute;
obtida com uma dose total di&aacute;ria de 160 a 320 mg/dia,
administrados em duas doses divididas. Alguns pacientes com arritmias
ventriculares refrat&aacute;rias com risco de vida podem necessitar
de doses t&atilde;o altas como 480 a 640 mg/dia; no entanto, estas
doses devem ser prescritas somente quando o benef&iacute;cio
potencial exceder o aumento do risco de eventos adversos,
particularmente pr&oacute;-arritmias. Devido &agrave; longa meia-vida
de elimina&ccedil;&atilde;o do Cloridrato de Sotalol, posologia maior
que duas vezes ao dia n&atilde;o &eacute; geralmente necess&aacute;ria.
</FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Nota:
Antes do in&iacute;cio da terapia com o Cloridrato de Sotalol,
agentes antiarr&iacute;tmicos pr&eacute;vios devem ser interrompidos,
sob cuidadosa monitoriza&ccedil;&atilde;o, por um per&iacute;odo
m&iacute;nimo de 2 a 4 meias-vidas da droga, se as condi&ccedil;&otilde;es
cl&iacute;nicas do paciente permitirem. Ap&oacute;s descontinua&ccedil;&atilde;o
de amiodarona, o Cloridrato de Sotalol n&atilde;o deve ser iniciado
at&eacute; que o intervalo QT seja menor que 450 mseg (ver Precau&ccedil;&otilde;es
e Advert&ecirc;ncias). O tratamento foi iniciado em alguns pacientes
recebendo lidoca&iacute;na intravenosa sem efeito prejudicial. Angina
pectoris/P&oacute;s-infarto do mioc&aacute;rdio: Recomenda-se que o
in&iacute;cio do tratamento em pacientes com cardiomiopatia ou
insufici&ecirc;ncia card&iacute;aca congestiva seja realizado em um
ambiente hospitalar. Dose inicial: 160 mg por dia em dose &uacute;nica
ou divididos em duas vezes. Ap&oacute;s a 1&ordf; semana de
tratamento, a dose inicial poder&aacute; ser aumentada, se
necess&aacute;rio, em at&eacute; 80 mg por semana. A rapidez pela
qual a dose &eacute; aumentada depende da toler&acirc;ncia do
paciente, em particular, medida pelo grau de bradicardia induzida e
resposta cl&iacute;nica. Devido a sua meia-vida relativamente longa,
o Cloridrato de Sotalol &eacute; eficaz na maioria dos pacientes
quando administrado uma vez ao dia. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Faixa
de dosagem: 160-320 mg/di&aacute;rios. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Posologia
em pacientes com disfun&ccedil;&atilde;o renal: devido ao Cloridrato
de Sotalol ser excretado predominantemente na urina e sua meia-vida
de elimina&ccedil;&atilde;o final ser prolongada na disfun&ccedil;&atilde;o
renal, a dosagem do Cloridrato de Sotalol deve ser reduzida quando a
creatinina s&eacute;rica for maior que 120 mcmol/l de acordo com a
seguinte tabela:</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>CREATININA
S&Eacute;RICA			DOSE RECOMENDADA</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>(&micro;mol/l)		(mg/dl)</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>&lt;
120			&lt; 1,2			Dose recomendada de sotalol</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>\u?
120-200		\u? 1,2 - &lt; 2,3		&frac34; da dose normal				</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>\u?
200-300		\u? 2,3 - &lt; 3,4		&frac12; da dose normal</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>\u?
300-500		\u? 3,4 - &lt; 5		&frac14; da dose normal</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
Cloridrato de Sotalol deve ser evitado ou usado com cautela em
pacientes com fun&ccedil;&atilde;o renal severamente diminu&iacute;da
(clearance de creatinina &lt; 10 ml/min).</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>
</FONT></FONT><BR>
</P>
<P STYLE="margin-bottom: 0cm; page-break-after: avoid"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Superdosagem
</FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Superdosagem
acidental ou intencional com Cloridrato de Sotalol raramente resultou
em morte. A hemodi&aacute;lise causa uma grande redu&ccedil;&atilde;o
dos n&iacute;veis plasm&aacute;ticos de sotalol. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Sintomas
e tratamento da superdosagem </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Os
sinais mais comuns esperados s&atilde;o bradicardia, insufici&ecirc;ncia
card&iacute;aca congestiva, hipotens&atilde;o, broncoespasmo e
hipoglicemia. Em casos de grande superdosagem intencional (2 a 16
gramas) de sotalol observa-se os seguintes resultados cl&iacute;nicos:
hipotens&atilde;o, bradicardia, prolongamento do intervalo QT,
complexo ventricular prematuro, taquicardia ventricular, &#147;Torsade
de Pointes&#148;. Se ocorrer superdosagem, a terapia com sotalol deve
ser descontinuada e o paciente rigorosamente observado. Al&eacute;m
disso, se necess&aacute;rio, as seguintes medidas terap&ecirc;uticas
s&atilde;o sugeridas: </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Bradicardia
- atropina, outra droga anti-colin&eacute;rgica, um agonista
beta-adren&eacute;rgico ou marca-passo transvenoso. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Parada
card&iacute;aca (segundo ou terceiro grau) - marca-passo card&iacute;aco
transvenoso.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Hipotens&atilde;o
(dependendo dos fatores associados) - epinefrina antes de
isoproterenol ou norepinefrina pode ser &uacute;til, dependendo dos
fatores associados. </FONT></FONT>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Broncoespasmo
- aminofilina ou estimulante de receptor beta-2 aerosol.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>&#147;Torsade
de Pointes&#148; - cardiovers&atilde;o DC, marca-passo transvenoso,
epinefrina e/ou sulfato de magn&eacute;sio.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Pacientes
idosos</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>A
fun&ccedil;&atilde;o renal comprometida nesses pacientes pode
diminuir o &iacute;ndice de elimina&ccedil;&atilde;o, resultando em
aumento do ac&uacute;mulo da droga.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>O
ajuste da dose deve ser feito a crit&eacute;rio m&eacute;dico,
baseado no hist&oacute;rico do paciente.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>-
Venda sob prescri&ccedil;&atilde;o m&eacute;dica.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>-
N&ordm; do lote, datas de fabrica&ccedil;&atilde;o e de validade:
vide embalagem externa.</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>M.S.
1.0089. 0281</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Farm.
Resp.: Alberto Ajncyer - CRF-RJ n&ordm; 6311</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Fabricado
por: Genpharm Inc. Etobicoke - ON - Canad&aacute;</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Comercializado
por: Merck S.A. Ind&uacute;strias Qu&iacute;micas</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>CNPJ
33.069.212/0001-84 - Estrada dos Bandeirantes, 1099</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Rio
de Janeiro - RJ - CEP 22710-571</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><FONT FACE="Arial, sans-serif"><FONT SIZE=2>Ind&uacute;stria
Brasileira</FONT></FONT></P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><FONT SIZE=2><FONT FACE="Arial, sans-serif">031920b/a</FONT></FONT></P>
</BODY>
</HTML>
                    </p>
                </div>
                
                <div class="tab-content video">
                    <p>
                        
                    </p>
                </div>
            </div>
            <div class="ch_clear" chaordic="middle"></div>
            
            <div class="ch_clear" chaordic="bottom"></div>
        </div>
    </div>
    <div class="zx_48A4A1065492484E8D54 zx_mediaslot">
       <script type="text/javascript">
           /*<![CDATA[*/
           window._zx = window._zx || [];
           window._zx.push({
               id: "48A4A1065492484E8D54"
           });
           (function (e) {
               var c = e.createElement("script");
               c.async = true;
               c.src = (e.location.protocol == "https:" ? "https:" : "http:") + "//static.zanox.com/scripts/zanox.js?utm_source=Zanox&utm_medium=Afiliados&utm_campaign=Desconto&acao=3&partner=576";
               var b = e.getElementsByTagName("script")[0];
               b.parentNode.insertBefore(c, b)
           }(document)); /*]]>*/
        </script>
        <script type="text/javascript">
            var images = window.chaordic_meta.product.images;
            var zx_identifier = window.chaordic_meta.product.id;
            var zx_name = window.chaordic_meta.product.name;
            var zx_price = window.chaordic_meta.product.price;
            var zx_url = window.location.host + window.chaordic_meta.product.url;
            var zx_photo = window.location.host + images["300x300"];
        </script>
        <script type="text/javascript">
            var IP;
            /*<![CDATA[*/
            function incrementValue() {
                var a = parseInt(document.getElementById("txt_QtdDP").value, 10);
                a = isNaN(a) ? 0 : a;
                a++;
                if (a == 21) {
                    a = 20
                }
                //if (a < 10) {
                //    a = ("0" + a)
                //}

                document.getElementById("txt_QtdDP").value = a
            }

            function DecrementValue() {
                var a = parseInt(document.getElementById("txt_QtdDP").value, 10);
                a = isNaN(a) ? 0 : a;
                a--;
                if (a == 0) {
                    a = 1
                }
                //if (a < 10) {
                //    a = ("0" + a)
                //}
                document.getElementById("txt_QtdDP").value = a
            }
            $("#txt_QtdDP").on("keyup blur", function (a) {
                $(this).val($(this).val().replace(/[^\d].+/, ""));
                if ((a.which < 48 || a.which > 57)) {
                    a.preventDefault()
                }


            });

            //$("#txt_QtdDP").on("keyup blur", function () {
            //    if ($("#txt_QtdDP").val() > 50) {
            //        $("#txt_QtdDP").val("0" + 1)
            //    }
            //    if ($("#txt_QtdDP").val() == "") {
            //        $("#txt_QtdDP").val("0" + 1)
            //    }
            //}); /*]]>*/




            $.get("https://ipinfo.io", function (response) {
                IP = response.ip;
            }, "jsonp");


            $("#cphConteudo_btComprarDP").click(function () {

                SalvarCRMProduto();
            });


            function SalvarCRMProduto() {

                $.ajax({
                    type: "POST",
                    url: "/DetalheProduto/Default.aspx/SalvarCrm",
                    data: "{id_produto:'" + $("#cphConteudo_hf_id_produto").val() + "',UF:'" + $("#cphConteudo_slCrmUF").val() + "',CRM:'" + $("#cphConteudo_txtCrm").val() + "',IP:'" + IP + "'}",
                    contentType: "application/json; charset=utf-8",
                    dataType: "json",
                    success: function (data) {
                        //if (data.d == "Salvo") {


                        //} else if (data.d == "Não Salvo") {

                        //}

                    },
                    error: function (data) {

                    }
                });

            }

        </script>
    </div>
    <style type="text/css">
		#lblProductName{
			text-transform:capitalize;
		}
	
        #cphConteudo_divSeloDermaclub {
            cursor: default;
        }

            #cphConteudo_divSeloDermaclub:hover {
                cursor: pointer;
            }
    </style>
    <script type="text/javascript">

     

    </script>

     <!-- SCRIPT MAPPER CLEARSALE -->
                                                                    <script>
                                                                        (function (a, b, c, d, e, f, g) {
                                                                            a['CsdmObject'] = e; a[e] = a[e] || function () {
                                                                                (a[e].q = a[e].q || []).push(arguments)
                                                                            }, a[e].l = 1 * new Date(); f = b.createElement(c),
                                                                                g = b.getElementsByTagName(c)[0]; f.async = 1; f.src = d; g.parentNode.insertBefore(f, g)
                                                                        })(window, document, 'script', '//device.clearsale.com.br/m/cs.js', 'csdm');
                                                                        csdm('app', '7cca55c77d');
                                                                    </script>
                                                <!--FIM SCRIPT MAPPER CLEARSALE -->


                <!-- conteudo -->
            </div>
        </div>
        <!-- FIM ESTRUTURA -->
        <!-- FOOTER -->
        <div class="pre-footer row">
            <div class="wrapper full">
                <div class="col newsletter">
                    <h5 class="news-title">Newsletter!</h5>
                    <p class="news-sub-title"><span>Cadastre-se</span></p>
                    <p class="text">Fique por dentro de todas as nossas promoções e descontos exclusivos.</p>
                    <input type="email" class="input-email" placeholder="Digite seu email" id="txtnewslettermaster" />
                    <a class="btn btn-acqua" onclick="AdicionarNewsLetter(1)">OK</a>
                    <p id="NewsLetterMaster" class="textNewsLetter"></p>
                </div>
                <div class="col cvs">
                    <p align="center">
                        <img class="img-cvs-health" src="https://www.onofre.com.br/assets/img/cvs-health-logo-grande.jpg" alt="CVS Health" />
                    </p>
                    <p class="text">Desde 2013, a Drogaria Onofre faz parte da maior empresa de saúde do mundo, CVS Health. Com mais de 7.500 drogarias distribuídas por todo o território americano, e 47 no Brasil. </p>
                    <a href="/Institucional/Default.aspx?InstId=230" class="btn btn-red" title="Saiba mais sobre a CVS Health">CLique aqui</a>
                </div>
                <div class="col lojas last">
                    <div class="info">
                        <h5>Nossas Lojas</h5>
                        <p class="text">A Drogaria Onofre possui 47 lojas em todo o território nacional e oferece mais de 15 horas de atendimento farmacêutico por dia.</p>
                        <a href="/nossaslojas/nossaslojas.aspx" class="btn btn-blue" title="Veja mais lojas">Clique aqui</a>
                    </div>
                    <img src="https://www.onofre.com.br/assets/img/banner-nossas-lojas.jpg" alt="Conheça nossas lojas" />
                </div>
            </div>
            <!-- /wrapper prefooter -->
        </div>
        <!-- /prefooter -->
        <footer class="page-footer">
                                        <div class="page-footer-top row">
                                            <div class="wrapper">
                                                <div class="row top-items">
                                                    
                                                            <div class="col4">
                                                                <h5 class="box-title">Sobre a Onofre</h5>
                                                                <ul class="links-list">
                                                                    
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=93' target='' class="list-link">
                                                                                    Quem Somos
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/nossaslojas/nossaslojas.aspx' target='' class="list-link">
                                                                                    Nossas Lojas
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.vagas.com.br/onofre' target='' class="list-link">
                                                                                    Trabalhe Conosco
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/nossaspoliticas' target='' class="list-link">
                                                                                    Nossas Políticas
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=207' target='' class="list-link">
                                                                                    Imprensa
                                                                                </a>
                                                                            </li>
                                                                        
                                                                </ul>
                                                            </div>
                                                        
                                                            <div class="col4">
                                                                <h5 class="box-title">Serviços</h5>
                                                                <ul class="links-list">
                                                                    
                                                                            <li class="list-item">
                                                                                <a href='https://portal.anvisa.gov.br/wps/portal/anvisa/informetecnico/!ut/p/c5/04_SB8K8xLLM9MSSzPy8xBz9CP0os3hnd0cPE3MfAwMDMydnA093Uz8z00B_A3dTU6B8JE55A38jArrDQfbh1w-SN8ABHA30_Tzyc1P1I_WjzBGmuBtamBt4WribujmFOhsbhBnqR-akpicmV-oX5EYYZJmEKgIAztfaUw!!/dl3/d3/L2d' target='_blank' class="list-link">
                                                                                    Alertas e Informes Anvisa
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.cff.org.br/' target='_blank' class="list-link">
                                                                                    Conselho Federal de Farmácia
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://portal.cfm.org.br/' target='_blank' class="list-link">
                                                                                    Conselho Federal de Medicina
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=25' target='' class="list-link">
                                                                                    Aplicativo Onofre para iPhone e Android
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='/mapa-site' target='' class="list-link">
                                                                                    Mapa do Site
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://portalsaude.saude.gov.br/index.php/o-ministerio/principal/secretarias/sctie/farmacia-popular' target='_blank' class="list-link">
                                                                                    Farmácia Popular
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/entregaRapida/' target='' class="list-link">
                                                                                    Entrega Rápida
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=275' target='' class="list-link">
                                                                                    Monte sua farmacinha
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=28' target='' class="list-link">
                                                                                    Confira condições de frete
                                                                                </a>
                                                                            </li>
                                                                        
                                                                </ul>
                                                            </div>
                                                        
                                                            <div class="col4">
                                                                <h5 class="box-title">Relacionamento</h5>
                                                                <ul class="links-list">
                                                                    
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/CentralCliente/Default.aspx' target='' class="list-link">
                                                                                    Central do Cliente
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/FaleConosco/' target='' class="list-link">
                                                                                    Fale Conosco
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/centralajuda/centralajuda.aspx' target='' class="list-link">
                                                                                    Central de Ajuda
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/falefarmaceutico/' target='' class="list-link">
                                                                                    Fale com o Farmacêutico
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://blog.onofre.com.br/' target='' class="list-link">
                                                                                    Blog da Onofre
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=97' target='' class="list-link">
                                                                                    Troca e Devolução
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://chat_online' target='' class="list-link">
                                                                                    Chat Online
                                                                                </a>
                                                                            </li>
                                                                        
                                                                </ul>
                                                            </div>
                                                        
                                                    <div class="col4 apps last">
                                                        <h5 class="box-title">Aplicativo Onofre</h5>
                                                        <p>Baixe os nossos aplicativos e tenha nossas ofertas na palma da mão</p> <span>Baixar Apps</span> <a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=25" target="_blank" class="app-link apple">Apple</a> <a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=25" target="_blank" class="app-link android">Android</a> </div>
                                                </div>
                                                <div class="row bottom-items">
                                                    <div class="col8">
                                                        <h6>Compre pelo telefone</h6>
                                                        <div class="tel">
                                                            <p>4007-2526</p>
                                                            <span>(Custo de uma ligação local)</span><br />
                                                            <span>Horário das 8h às 21h, de segunda a sábado</span>
                                                        </div>                                                        
                                                        <div class="tel" style="float:right" >
                                                            <p>0800-609-3030</p> <span>Demais localidades</span> 
                                                        </div>
                                                    
                                                        <div class="col8" style="margin: 10px 0px 0px 0px"> Caro cliente, a Drogaria Onofre informa que, temporariamente, os pedidos realizados no site após às 21h de sábado serão processados na segunda-feira, a partir das 8h. Desta forma, ressaltamos que o prazo de entrega da sua compra
                                                            <br> será calculado a partir desta data. </div>
                                                    </div>
                                                    <div class="col5 social">
                                                        <h6>Acompanhe a Onofre</h6>
                                                        <ul class="social-links">
                                                            <li class="social-item"><a class="social-link facebook" href="https://www.facebook.com/DrogariaOnofreOficial" class="social-link facebook" target="_blank" title="Facebook">Facebook</a></li>
                                                            
                                                                <li class="social-item"><a href="https://www.instagram.com/drogariaonofre/" class="social-link instagram" target="_blank" title="Instagram">Instagram</a></li>
                                                                <li class="social-item">
                                                                    <a href="https://blogonofre.wordpress.com" target="_blank"> <img src="https://www.onofre.com.br/assets/img/be-onofre-logo.jpg" alt="Be onofre" /></a>
                                                                </li>
                                                        </ul>
                                                    </div>
                                                </div>
                                            </div>
                                            <!-- /wrapper page-footer-top -->
                                        </div>
                                        <!-- /page-footer-->
                                        <div class="page-footer-bottom row">
                                            <div class="wrapper">
                                                <div class="col8">
                                                    <p class="title-box">Formas de pagamento</p> <img class="img-formas-pagamento-master" src="https://www.onofre.com.br/assets/img/formas-de-pagamento.jpg" alt="Visa, MasterCard, Amex, Diners, Hipercard, Aura e Boleto bancário" /> </div>
                                                <div class="col5 seguranca">
                                                    <p class="title-box">Segurança</p>
                                                    <ul class="selos">
                                                        <li>
                                                            <a id="seloEbit" href="https://www.ebit.com.br/onofre-em-casa" target="_blank" onclick="redir(this.href)" style="background-image: url(&quot;https://a248.e.akamai.net/f/248/52872/0s/img.ebit.com.br/ebitBR/selo/img_973.png&quot;); width: 89px; height: 95px; display: block; overflow: hidden; position: relative; float: left" title="Avaliado pelos consumidores"></a>
                                                        </li>
                                                        <li>
                                                            <!-- COMODO -->
                                                            <script language="javascript" type="text/javascript">
                                                                /*<![CDATA[*/
                                                                var tl_loc0 = (window.location.protocol == "https:") ? "https://secure.comodo.net/trustlogo/javascript/trustlogo.js" : "https://www.trustlogo.com/trustlogo/javascript/trustlogo.js";
                                                                document.writeln('<script language="JavaScript" src="' + tl_loc0 + '" type="text/javascript"><\/script>'); /*]]>*/
                                                            </script>
                                                            <!-- COMODO -->
                                                            <script language="JavaScript" type="text/javascript">
                                                                TrustLogo("https://www.onofre.com.br/img/Rodape/comodo.png", "SC5", "none");
                                                            </script>
                                                        </li>
                                                    </ul>
                                                </div>
                                            </div>
                                            <!-- /wrapper page-footer -->
                                        </div>
                                        <!-- /page-footer-bottom -->
                                        <div class="row">
                                            <div class="wrapper"> <address class="col16"> <span id="lblDescriptionAddress"><p align="center"><span style="color: #888888;">Drogaria Onofre Ltda | CNPJ 61.549.259/0013-14 | IE 115.276.053.114 | Av. da Liberdade, 902 Complemento 904 - Liberdade | São Paulo (SP) | Horário de funcionamento: Segunda a Domingo 07:00 às 22:00 | CEP: 01502-001 | Telefone 4007-2526</span><br /><span style="color: #888888;">Farmacêutico Responsável: Dra. Thais Briotto de Andrade dos Santos | CRF - SP: 53.912 | AFE: 7.46544-5 | CMVS: 35503080147700867012</span></p>
<p align="center"><span style="color: #888888; font-family: tahoma, arial, helvetica, sans-serif; font-size: x-small;">As informações contidas neste site não devem ser usadas para automedicação e não substituem, em hipótese alguma, as orientações dadas pelo profissional da área médica. Somente o médico está apto a diagnosticar qualquer problema de saúde e prescrever o tratamento adequado. Ao persistirem os sintomas, o médico deverá ser consultado. Os preços e promoções divulgados no site são válidos apenas para compras feitas pela Internet e podem variar conforme região de entrega. Em caso de divergência, o preço válido é o do carrinho de compras. Imagens meramente ilustrativas. Este site é melhor visualizado na configuração 1024x768.</span><br /><span style="color: #888888; font-family: tahoma, arial, helvetica, sans-serif; font-size: x-small;">Copyright © 1999 - 2016 Onofre em Casa. Todos os direitos reservados.</span><br /><span style="color: #888888; font-family: tahoma, arial, helvetica, sans-serif; font-size: x-small;">*Desconto não válido para todos os produtos dessa página</span></p></span> </address>
                                                 </div>
                                        </div>
                                        <!-- /wrapper copyright -->
                                        </div>
                                        <div id="armored_website">
                                            <param id="aw_preload" value="true" /> </div>
                                        <script type="text/javascript" src="//selo.siteblindado.com/aw.js"></script>
                                        <!-- /copyright -->
                                    </footer>
        <!-- /page-footer -->
        <!-- FIM FOOTER -->
        
    </form>
    <!-- Script Chat online-->
    <script>
        var chat_online = $("a[href='https://chat_online']").removeAttr("href");
        chat_online.click(function (event) { window.open("https://onofre.custhelp.com/app/chat/chat_launch", "Chat Online Drogaria Onofre", "top=80,left=900,width=475,height=715"); });
    </script>
    <!--END chat online -->


    <!-- ------------------------------------------------------------------------------------------------------------- -->
    <!-- -------------------------------------------------- SCRIPTS -------------------------------------------------- -->
    <!-- ------------------------------------------------------------------------------------------------------------- -->
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//www.googletagmanager.com/ns.html?id=GTM-5SFH26" height="0" width="0" style="display: none; visibility: hidden"></iframe>
    </noscript>
    <script>
        /*<![CDATA[*/
        (function (f, d, l, i, n) {
            f[i] = f[i] || [];
            f[i].push({
                "gtm.start": new Date().getTime(),
                event: "gtm.js"
            });
            var j = d.getElementsByTagName(l)[0],
                o = d.createElement(l),
                p = i != "dataLayer" ? "&l=" + i : "";
            o.async = true;
            o.src = "//www.googletagmanager.com/gtm.js?id=" + n + p;
            j.parentNode.insertBefore(o, j)
        })(window, document, "script", "dataLayer", "GTM-5SFH26"); /*]]>*/
    </script>
    <!-- End Google Tag Manager -->
 


      <script>

          var AbertoLoginBox = false;


          function ExibirPopupLogin(a, b, c) {
              $.colorbox({
                  href: a,
                  open: !0,
                  iframe: !0,
                  scrolling: !0,
                  opacity: .5,
                  overlayClose: false,
                  transition: "fade",
                  height: c,
                  width: b,
                  fixed: !0,
                  closeButton: true,
                  className: "colorbox_login",

              });

              AbertoLoginBox = true;

              $(document).bind('cbox_complete', function () {

                  $("#cboxClose").hide();
                  $("#cboxClose").html("X");
                  $("#cboxClose").attr("class", "fecharBoxLogin");
                  $("#cboxClose").css("text-indent", "0px")
                  $("#cboxClose").css("text-indent", "0px")
                  $("#cboxClose").css("border", "2px solid rgb(216, 216, 216)")
                  $("#cboxClose").css("background-color", "white")
                  $("#cboxClose").css("color", "rgb(216, 216, 216)")
                  $("#cboxClose").css("top", "2px")
                  $("#cboxClose").css("right", "2px")                 
                  $("#cboxClose").show();

                  $("#cboxClose").click(function () {

                      $.colorbox.close();

                  });

                 
              }); 

          }

      </script>
      <script type="text/javascript">

        setTimeout(function () {
            var url = "../../../Jss/Colorbox/jquery.colorbox-min.js";
            $.getScript(url, function () {
                console.log("jquery.colorbox-min Carregado!");
            });
        },1300);

    </script>
    
    <!-- ------------------------------------------------------------------------------------------------------------- -->
    <!-- -------------------------------------------------- SCRIPTS -------------------------------------------------- -->
    <!-- ------------------------------------------------------------------------------------------------------------- -->
     
</body>
<link href="assets/css/chaordic.css" rel="stylesheet" />


</html>
